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ABSTRACT 
TOWARDS AN ATOMIC LEVEL MODEL OF THE STRUCTURE AND CALMODULIN MEDIATED 
ACTIVATION OF EEF-2K 
 
by 
Nathan Will 
Advisor: Ranajeet Ghose 
 
Eukaryotic elongation factor 2 kinase (eEF-2K), the only calmodulin (CaM) dependent member of 
the α-kinase, phosphorylates eukaryotic elongation factor 2 (eEF-2) on a specific residue (Thr-56), 
decreasing its affinity for the ribosome and reducing the rate of peptide chain elongation during protein 
translation. In contrast to the “release-of-inhibition’ mechanism operative in most CaM-dependent proteins 
kinases, the activation of eEF-2K is proposed to occur through a two-step process subsequent to the 
engagement of CaM and involves (1) auto-phosphorylation on T348 and (2) engagement of an allosteric 
site by phospho-T348 leading to a state with the highest activity towards the substrate eEF-2. The precise 
mechanism of this CaM-mediated activation of eEF-2K and the mode of recruitment of the substrate 
remain poorly understood.  
We utilized a variety of complimentary biophysical techniques including nuclear magnetic 
resonance spectroscopy (NMR), small angle X-ray scattering (SAXS), and multiple high-resolution mass 
spectrometric (MS) methods to determine the mechanisms through which CaM engages eEF-2K and 
induces conformational changes therein en route towards its fully active state. Our integrative approach 
provides structural insights into the engagement of eEF-2K by CaM and represents an essential first step 
in defining the CaM-dependent activation of eEF-2K in atomistic detail. 
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Chapter 1 – Introduction 
1.1 – Regulation of Protein Translation 
Regulation of protein translation is a key cellular process that is critical for cellular growth, 
development, differentiation and survival; its dysregulation is key in a variety of cancers and neurological 
conditions such as Alzheimer’s disease.1–12 While necessary for cellular growth and survival, protein 
synthesis is an energetically expensive process that requires strict regulation to maintain cellular 
homeostasis.2,10 The ability to conserve energy by slowing the rate of translation is especially critical 
under stress conditions such as starvation or the hypoxic environment of solid tumors.3,4,6,9,10 Additionally, 
regulation of protein synthesis in neurons has been shown to play a critical role in diverse neurological 
processes and disorders.11–15 Cells utilize a variety of factors to regulate protein synthesis to respond to 
their changing energetic and biosynthetic requirements.2,10,16–18 
Protein translation can be divided into three phases: initiation, elongation, and termination.2,10,16–18 
The most highly regulated of these three phases is initiation.1,2 During the initiation phase of translation, 
eukaryotic initiation factors (eIFs) recognize the m7G cap structure at the 5’ end and the poly(A) tail at the 
3’ end and facilitate pre-initation complex (PIC) binding. The PIC identifies the AUG start codon by 
scanning from the 5’ untranslated region (UTR) towards the 3’ end of the mRNA. Once the AUG start 
codon is identified, the PIC recruits the 60S subunit of the ribosome to allow initiation of the elongation 
phase. Regulation of eIFs, RNA specific binding proteins, and microRNAs as well as structural elements 
within the mRNA have been shown to regulate the rate of translation initiation.1,19–24 This regulation of the 
initiation phase allows rapid response to cellular stresses by up-regulating or down-regulating production 
of specific proteins.1,22,23,25 In response to more ribosomes binding to a mRNA molecule due to increased 
initiation, the rate of elongation must also increase to avoid the elongation phase becoming the rate 
limiting step of translation.2,23,25,26 
Regulation of translation elongation serves multiple purposes. In addition to accommodating 
increased rates of translation initiation, decreasing the rate of the elongation during periods of slow 
initiation allows polysomes to be retained on the mRNA.2 Having mRNA preloaded with polysomes allows 
for rapid increases in the production of proteins when the needs of the cell switch from low to high rates of 
 2 
protein synthesis. Additionally, the rate of elongation is inversely proportional to the error rate during 
translation.27 Thus, slowing down translation increases the fidelity of protein synthesis and further 
incentivizes cells to regulate the elongation phase of translation. The elongation phase is also the most 
energetically expensive step of protein translation.2,10 Thus, slowing down global elongation rates is 
therefore an effective way to reduce the energy demands of the cells during periods of nutrient 
deprivation.  
The elongation phase of translation primarily depends on three proteins: eukaryotic elongation 
factor-1 alpha (eEF-1α), eukaryotic elongation factor-2 (eEF-2) and eukaryotic elongation factor-3 (eEF-
3).2,10,16–18 eEF-1α and eEF-3 are responsible for aminoacyl-tRNA recruitment, while eEF-2 catalyzes the 
GTP-dependent translocation of tRNA from the A-site to the P-site of the ribosome.2,10,16–18 
Phosphorylation of eEF-2 at Thr-56 decreases its affinity for the ribosome, thus slowing protein 
translation.17,18,28 An atypical protein kinase called eukaryotic elongation factor 2 kinase (eEF-2K), 
previously referred to as calmodulin-dependent protein kinase III, was shown to be responsible for this 
phosphorylation.29–34 eEF-2K is a calmodulin (CaM) dependent protein kinase, which itself is regulated by 
diverse mechanisms such as phosphorylation, ubiquitination mediated degradation, pH, and indirectly by 
the cytoplasmic calcium concentration through CaM-mediated activation.35–37 Our long-term is focused on 
characterizing the regulation of eEF-2K to further understand its function in normal cellular activity and 
disease states such as cancer and depression. 
1.2 – Role of eEF-2K in Normal and Diseased States 
1.2.1 – Learning, Memory, and Depression 
 It is well established that protein translation occurs both within the cell body as well as that 
dendrites of neurons.38,39 This allows rapid protein synthesis at synapses, which can be relatively distant 
from the cell body of the neuron, and local regulation of protein expression at the synaptic level.13,39 
Synaptic plasticity, through which the strength of a synapse is modified, has been suggested to be 
dependent on protein synthesis. Regulation of protein translation has also been shown to play a critical 
role in memory consolidation and long term potentiation (LTP), a type of synaptic plasticity in which a 
synapse is strengthened in response to patterns of signaling.11–15 Additionally, expression of proteins that 
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regulate translation have been shown to be increased in specific brain regions associated with the 
memory task studied.21,40 As a result of these functions, regulation of both the initiation and elongation 
phases of translation have been implicated in learning and memory formation.13,21,40–42 
 The role of protein synthesis in synaptic plasticity as well as the role of calcium ions as a 
secondary messenger downstream of neurotransmitter signaling makes eEF-2K well positioned to act as 
an intermediary connecting local protein translation to synaptic activity.43 It has been shown that eEF-2K 
directly interacts with Group I metabotropic glutamate receptors (mGluR) through the protein Homer. eEF-
2K dissociates from mGluR upon activation of the receptor, allowing it to phosphorylate eEF-2 which is 
coupled to an increase in the expression of Arc/Arg3.1.43,44 Mice with kinase dead eEF-2K have been 
shown to exhibit attenuation of cortical-dependent associative taste learning, further demonstrating a 
direct role of this pathway in learning and memory.14 
 In addition to its critical function in normal neuronal signaling, eEF-2K has drawn interest for its 
role in the rapid antidepressant effects of ketamine.43,45,46 Ketamine is an NMDA receptor inhibitor that 
exhibits antidepressant activity in patients with depression that is resistant to other treatments.45 
Suppression of spontaneous NMDA receptor mediated neurotransmission induces rapid potentiation of 
synaptic responses in the CA1 region of the hippocampus, a region of the brain critical for the activity of 
antidepressants.46 This potentiation requires rapid translation of brain-derived neurotrophic factor (BDNF) 
and increased expression of AMPA receptors at the cell surface, which are both dependent on eEF-2K 
activity.46 These results suggest that modulators of eEF-2K activity could be useful in the treatment of 
clinical depression. 
1.2.2 – Cancer 
In addition to its role in normal cellular functions, eEF-2K has been implicated in certain types of 
cancer such as glioblastomas, medulloblastomas,3 and breast cancer.25 It has been shown that eEF-2K 
inhibition by siRNA knockdown can sensitize the highly aggressive triple negative MDA-MB-231 tumors to 
Doxorubicin, a chemotherapy agent, in orthotopic xenograft models.5 Additionally, it has been suggested 
that breast cancer cells can acquire resistance to hypoxia by uncoupling oxygen-responsive signaling 
pathways from inhibition of protein synthesis mediated by eEF-2K.24 It is also thought that eEF-2K has an 
integral role in regulation of the Warburg effect by controlling the production of protein phosphatase 2A-
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A.47 Addition of eEF-2K inhibitors in combination with chemotherapy agents could be a promising 
approach for treating some types of cancer. Contrary to these results, it has also been proposed that 
eEF-2K could block tumorigenesis under some conditions.43 While inhibition of eEF-2K shows promise for 
the treatment of a subset of cancer types, more work is needed to fully define the role of eEF-2K in 
cancer. Structural characterization of eEF-2K and delineation of the mechanisms through which it 
becomes active is critical to understanding the role of this protein in normal biological processes and 
disease. 
1.3 – Domain Organization of eEF-2K 
The structure of full-length eEF-2K is as of yet unknown. A variety of biochemical and 
truncation/deletion studies coupled with sequence analyses has defined the organization shown in Figure 
1.1. eEF-2K contains an α-kinase domain (residues 116-336) and a SEL-1 like repeat (SLR) containing 
C-terminal region connected by an extended, presumably flexible, regulatory loop (R-loop) that contains 
multiple up- and down-regulating phosphorylation sites. N terminal to the kinase domain is a region of 
which contains a non-canonical CaM binding sequence (Figure 1.1).35,48–52 Calcium-bound calmodulin 
(Ca2+/CaM) has been shown to interact with residues 79-96 of eEF-2K thus leading it to be referred to as 
the calmodulin binding domain (CBD).36,48,49,53 C-terminal the kinase domain, is the R-loop that contains 
the primary site for activating auto-phosphorylation T348. (Figure 1.1).36,48–50 Phosphorylation of T348 has 
been shown to be critical for full activation of the kinase (Figure 1.2).36,54 The phosphorylated T348 has 
been proposed to interact with a conserved phosphate binding pocket on the C lobe of the kinase.37  
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Figure 1.1 - Domain structure of eEF-2K. The organization of domains within eEF-2K is shown. The 
calmodulin binding domain (CBD) is shown in orange, the alpha kinase 
 domain is shown in yellow, the regulatory R-loop is shown in tan, and the C terminal domain is shown in 
blue. Regulatory phosphorylation sites are shown as circles containing the residue number from human 
eEF-2K. Sites that increase the activity of eEF-2K are shown in green, while phosphorylation sites that 
down regulate the activity are colored red. The kinases that phosphorylate each phosphorylation site are 
indicated with arrows. The SEL1 like repeats within the CTD are shown as purple boxes. The domains in 
this figure are not drawn to scale.   
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Figure 1.2 – Proposed two-step mechanism for eEF-2K activation. Resting eEF-2K (state S1) forms a 
complex with by calcium bound calmodulin (state S2*, an “excited” state that may or may not be 
experimentally observable) and undergoes a conformation transition (T1) to a state (S2) that is able to 
phosphorylate on T348 in a highly efficient fashion. After rapid auto-phosphorylation on T348 leading to 
an excited state S3*, enables phosphorylated T348 to interact with a phosphate binding pocket on the C 
lobe of the kinase domain, leading to a second conformation transition (T2), generating a state of eEF-2K 
(S3) that has the highest activity towards its substrate eEF-2. Additional regulatory phosphorylation 
events modulate this activation process through yet unknown mechanisms. 
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1.3.1 – CaM Binding Domain 
The CaM binding domain of eEF-2K (CBD) is located N terminal to the alpha kinase domain, and 
has been shown to be critical for activation of eEF-2K (Figure 1.1).49,51 Most CaM dependent kinases are 
activated by CaM sequestering an inhibitory peptide through the so-called “release of inhibition” 
mechanism.55,56 Deletion of the eEF-2K CBD results in a reduction of kinase activity rather than an 
increase as would be expected by the removal of an inhibitory segment, suggesting that eEF-2K is 
activated by CaM through an alternative mechanism.49,51,55,57 The structure of the Ca2+/CaM-CBD 
complex, recently published by our lab, determined that the CBD interacts primarily with the C lobe of 
CaM in an antiparallel 1-5-8 hydrophobic mode reinforced by a pair of electrostatic interactions.53 
Interestingly, our data suggests that two calcium ions bind to the N lobe of CaM, while the C lobe Ca2+ 
binding sites appear to be vacant when in complex with the CBD (see Chapter 5 and Lee, et al.).53 
Additionally, it was shown that W85 of eEF-2K acts as a hydrophobic anchor, stabilizing its interaction 
with CaM. Mutation of this residue to serine (eEF-2K W85S) significantly weakens the interaction 
between CaM and eEF-2K, as well as reducing eEF-2 phosphorylation in cells.49,53 
1.3.2 – α-Kinase Domain 
Historically, eEF-2K was thought to belong to the CaM-dependent protein kinase family (eEF-2K 
was previously referred to as CaMK-III) because calcium-bound CaM is necessary for 
autophosphorylation and activation of the kinase (Figure 1.2).29,51,58 However, it was discovered to contain 
an atypical kinase domain which belongs to the α-kinase family.29,30 α-kinases show low sequence 
homology to the canonical protein kinases (CPKs),29,30,50 though crystal structures of the catalytic 
domains of α-kinases display striking structural similarity to those of canonical protein kinases.50,59 Similar 
to canonical kinases,  α-kinase domains contain an N-terminal lobe that is composed primarily of curved 
β-sheets and a C-terminal lobe that largely consists of α-helices.50 A deep cleft between the two lobes 
contains the ATP binding site.50,59 The most significant difference between canonical and alpha kinase 
families is a conserved zinc binding motif in the C-terminal lobe of the alpha kinase domain.50,59 
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1.3.3 – C-terminal Domain  
The C-terminal domain (CTD) of eEF-2K is predicted to contain a series of SEL-1 like helical 
repeat motifs (SLRs).48,52 The SLR family is characterized by a series of small and large hydrophobic 
residues with no position being completely invariant. Despite the low sequence homology, SLRs display a 
characteristic α-helical architecture.60,61 The SLRs with known functions are often involved in the 
assembly of macromolecular complexes.60,61 Similarly, the CTD of eEF-2K has been suggested to be 
important for eEF-2 recruitment to the kinase domain.48,49,51 
It has been demonstrated that the C terminal region of eEF-2K (336-725) can bind eEF-2 in 
vitro.48 Deletion mutations between residues 521-725 have also been shown to inhibit phosphorylation of 
eEF-2, but not autophosphorylation or phosphorylation of the MH-1 (a peptide substrate of eEF-2K), 
suggesting that this region is involved in eEF-2 binding.35,48,49,51 Additionally, mutation of two conserved 
tyrosines (Y712 and Y713) of eEF-2K to alanine similarly results in loss of its ability to phosphorylate 
eEF-2.48 Our results suggest that these residues are structurally important and that mutation to alanine 
results in unfolding of the region (see Chapter 4).52 Additionally, this region in isolation is not able to 
outcompete eEF-2K for eEF-2 binding. Taken together this data suggests that the extreme C-terminus of 
the CTD does not contain the complete eEF-2 binding site.52 
1.4 – Regulatory Elements of eEF-2K 
The CBD and R-loop of eEF-2K comprise the primary regulatory regions of eEF-2K (Figure 1.2). 
eEF-2K activation is a multistep process involving binding Ca2+/CaM and rapid autophosphorylation of 
Thr348 (see Figure 1.2).36 This primary process is modulated by additional phosphorylation events, e.g. 
activation of the mTOR pathway results in inhibitory phosphorylation of eEF-2K within the R-loop on S78, 
S359, and S366.48,62,63 Phosphorylation of S78 is thought to inhibit eEF-2K activity by interfering with CaM 
binding.48,64 S359 is phosphorylated by the CDC2 – Cyclin B65 as well as stress-activated protein kinase 
(SAPK) 2a/p38δ66. Phosphorylation of eEF-2K by p70 S6 kinase (an mTOR activated kinase) on S366 
results in decreased phosphorylation of eEF-2 by eEF-2K in vitro.63 
Also contained within the R-loop are phosphorylation sites that are targeted by AMPK (S398) and 
PKA (S500; this is also a site for secondary auto-phosphorylation) that enhance the activity of eEF-
2K.64,67 Additionally, the R-loop contains a ubiquitin phospho-degron motif (residues 440-445), which 
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target eEF-2K for proteosomal degradation.37,68–70 Phosphorylation of eEF-2K by AMPK at S398 or PKA 
at S500 have been shown to induce ubiquitination and subsequent degradation of eEF-2K.  Interestingly, 
phosphorylation of eEF-2K on S500, by auto-phosphorylation or by the activity of PKA, results in calcium 
independent activation of the eEF-2K-CaM complex.36 An S500D mutation mimics the behavior of 
phosphorylated S500 in cells, providing a convenient tool to study the structural mechanism of calcium 
independent activation of eEF-2K.36  
1.4.1 – Calmodulin-mediated Activation of eEF-2K 
 Typically, CaM-dependent kinases are activated through CaM sequestering an auto-inhibitory 
peptide.55,71 The mechanism of CaM-mediated eEF-2K activation does not appear to follow this model as 
no inhibitory peptide has been identified; further the deletion of the CBD does not increase the activity of 
eEF-2K, nor does it lead to a substantial increase in the affinity for the substrate eEF-2.48,49,51 A 
combination of steady and pre-steady-state kinetics measurements, in vitro and cell-based assays 
suggest that eEF-2K is activated through a two-step process which appears to be unique among the CaM 
dependent kinases (this process is schematically illustrated in Figure 1.2).37 We have demonstrated that 
CaM directly interacts with the N lobe of the kinase in addition to the CBD, stabilizing the P-loop, which is 
critical for catalysis (Chapter 5). The phosphate-binding pocket of the eEF-2K kinase domain is also 
stabilized, likely through an allosteric mechanism (Chapter 5). 
1.4.2 – Activation of eEF-2K by Thr348 Autophosphorylation 
 It has previously been shown that T348 of eEF-2K is rapidly auto-phosphorylated following Ca2+-
CaM binding.36 Mutagenesis studies and structural homology to the MHCK-A kinase domain suggest that 
phosphorylated T348 interacts with a phosphate binding pocked on the C-lobe of the eEF-2K kinase 
domain.37 This interaction can be mimicked by inorganic phosphate in the activation of eEF-2K; however 
a T348D does not replicate the effect of phosphorylation on T348, suggesting a phosphate-specific 
interaction is necessary to activate the kinase.37 Interestingly, our data suggests that there is allosteric 
communication between CaM binding and the phosphate-binding pocket of eEF-2K as described further 
in Chapter 5. 
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Chapter 2 – Optimization of eEF-2K Expression 
2.1 – Serial Truncation of the eEF-2K Kinase Domain Identified a Minimal Construct Necessary for 
Kinase Domain Expression 
Serial deletion from the N-terminus of eEF-2K (eEF-2K1-358 to eEF-2K111-358) was performed to 
identify a minimal N-terminal construct that could be expressed in E. coli. It was found that deletion of the 
N-terminal residues of eEF-2K up to 100 could be tolerated, though deletion of 1-110 resulted in no 
protein expression. This is in agreement with the homology model37 of the kinase domain in which E110 
of eEF-2K is part of a β-sheet that forms the β-barrel of the kinase domain N-lobe. The model also shows 
interaction between the side chains of eEF-2K E110 and R220 (Figure 2.1). While expression was seen 
for these N-terminal constructs, they did not appear to be properly folded and a minimal amount was 
obtained in the soluble fraction with almost all of the expressed protein being localized in the insoluble 
fraction.  
2.2 – Co-expression with the eEF-2K C-Terminal Domain Solubilizes the Kinase Domain  
 It has previously been shown that the C-terminal domain of eEF-2K is critical for eEF-2 
phosphorylation.48,49,51 Additionally, overexpression of the isolated N-terminal constructs encompassing 
the kinase domain (KD) in E. coli leads to formation of insoluble aggregates as mentioned above. Despite 
extensive buffer screening, no condition that yielded a soluble KD in isolation could be identified. The 
buffer conditions screened included pH from 6.5 to 8 (in steps of 0.5 pH) and sodium chloride 
concentrations of 100 mM, 250mM, or 500 mM. Further, additives including glycerol (1%, 2%, or 5%), 
Triton X-100 (0.1% v/v), magnesium chloride (1 mM), magnesium sulfate (1 mM), calcium chloride (1 
mM), were also tested without success. While a small fraction of the KD domain was observed in the 
soluble fraction immediately after lysis, it was found to form soluble aggregates on gel-filtration that 
rapidly precipitated out of solution upon concentration. 
Similarly, efforts to refold the KD from the inclusion bodies also failed to yield soluble protein. 
Briefly, the KD (eEF-2K1-358) containing inclusion bodies were harvested from E. coli lysates by 
centrifugation at 15,000 × g. The insoluble pellet was resuspended in lysis buffer (20 mM Tris, 100 mM 
NaCl, 2 mM DTT pH 7.5). Inclusion bodies were then dissolved with 8 M urea and the insoluble fraction 
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was removed by centrifugation at 15,000 × g. The solubilized fraction was then collected and slowly 
dialyzed against refolding buffer (20 mM Tris, 100 mM NaCl, 2 mM DTT pH 7.5) overnight. Removal of 
urea resulted in the KD precipitating back out of solution. α-kinases have been shown to contain a zinc 
ion in the C-lobe.72 To test if zinc ions were necessary for refolding, 1 mM zinc chloride was added to the 
refolding buffer without the desired effect.  
Constructs containing the KD (eEF-2K1-358 and eEF-2K71-358) were successfully produced in a 
stable folded form by co-expression with the C-terminal domain of eEF-2K (data for eEF-2K1-358 shown in 
Figure 2.2). A series of C-terminal domain constructs including eEF-2K470-725, eEF-2K480-725, eEF-2K490-725, 
eEF-2K520-725, and eEF-2K562-725 were co-expressed with eEF-2K1-358. The N-terminal construct formed 
stable and soluble complexes with eEF-2K470-725, eEF-2K480-725, eEF-2K490-725, and eEF-2K520-725, fully 
rescuing the KD from the insoluble fraction. In contrast, addition of eEF-2K490-725 to the lysis buffer was 
unable to rescue eEF-2K1-358 from inclusion bodies, suggesting that the presence of the C terminal 
domain during expression is important for proper folding of the KD. 
 
 
 
Figure 2.1 – Model of the eEF-2K kinase domain suggests E110 is important for kinase domain 
folding. A homology model of the eEF-2K KD is shown in green. Deletion of residues eEF-2K 108-110 
(cyan) was observed to be deleterious to KD expression.  Polar interactions between the side chains of 
E110 (cyan) and R220 (red) of eEF2K is shown as a yellow dashed line. 
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Figure 2.2 – Co-expression of the eEF-2K kinase domain (eEF-2K1-358) with the C-terminal domain 
(eEF-2K490-725) yields a stable heterodimeric complex. (A) Size exclusion traces eEF-2K1-358 co-
expressed with eEF-2K490-725 (red) and Full-length eEF-2K (blue) show that the presence of the C-terminal 
domain yields a homogeneous well folded protein. (B) SDS PAGE analysis of the major peak of the eEF-
2K1-358eEF-2K490-725 complex shows that this species contains both the kinase and C terminal domains of 
eEF-2K. Elution volumes contained by each fraction are shown in red on the size exclusion trace. 
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 Co-expression of eEF-2K1-358 (or eEF-2K71-358) with eEF-2K562-725 rescued the former from 
inclusion bodies, though this truncated C-terminal domain construct did not lead to the formation of a 
stable heterodimeric complex, but rather dissociated during purification, resulting in a soluble eEF-2K562-
725 and an aggregated eEF-2K71-358 (Figure 2.3). However, addition of eEF-2K490-725 to the N-terminal 
construct co-expressed with eEF-2K562-725 resulted in eEF-2K490-725 outcompeting the lower affinity eEF-
2K562-725 and the formation of a stable eEF-2K1-358•eEF-2K490-725 (Figure 2.4). The advantage of this 
system is that it can be utilized to isotopically label only one of the components of the stable complex 
since they are expressed independently.  Partial labeling of the complex will reduce the spectral 
complexity and facilitate analysis of the complex by NMR.  However, further optimization is needed to 
improve the efficiency and yield of the resulting complex. 
2.3 – Optimization of Solution Conditions for the NMR Analysis of the C-terminal Domain of eEF-
2K. 
While a homology model of the eEF-2K KD has been generated from the structure of another α-
kinase, MHCK-A, and has been proven to be robust through functional analysis,37 the C-terminal domain 
of eEF-2K does not show significant sequence homology to any entity for which a structure is available in 
the PDB. While crystallographic approaches were pursued to determine the structure of the C-terminal 
domain; these efforts did not yield protein crystals suitable for structural analysis. Additionally, the largest 
C-terminal domain construct that was tested eEF-2K490-725 exhibits concentration dependent aggregation, 
exchanging between a monomeric and soluble oligomeric states (Figure 2.5), complicating its NMR. 
Hence a divide-and-conquer approach was used to determine the structure of the C-terminal domain by 
NMR (see Chapters 3 and 4). 
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Figure 2.3 – Co-expression of the N-terminal construct of eEF-2K1-358 with a truncated C-terminal 
domain construct (eEF-2K562-725) solubilizes the kinase domain but does not result in a stable 
complex. (A) Size exclusion traces of eEF-2K1-358 co-expressed with eEF-2K490-725 rescued the former 
from inclusion bodies but eluted as two distinct peaks during size exclusion chromatography using a 
Superdex200 10/300 column. The N-terminal construct was found predominantly elute in the void 
fractions (~8 mL), while eEF-2K562-725 eluted as a monomeric peak centered at ~16 mL elution volume. (B) 
SDS PAGE analysis of the size exclusion chromatography fractions from the void (fractions 1-3) and the 
low molecular weight species (fractions 4-7) demonstrate that the KD-containing N-terminal construct was 
unable to form a stable complex with eEF-2K562-725.  
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Figure 2.4 – A truncated C-terminal domain (eEF-2K562-725) in complex with the KD (eEF-2K1-358) can 
be displaced by a longer C-terminal domain construct (eEF-2K490-725) resulting in a stable 
heterodimeric eEF-2K1-358eEF-2K490-725 complex. eEF-2K1-358 was co-expressed with eEF-2K562-725 
resulting in soluble aggregates. Purified eEF-2K490-725 was added to the soluble fraction and the mixture 
was purified over Ni-NTA followed by size exclusion chromatography. (A) Size exclusion traces and (B) 
SDS PAGE analyses of the relevant fractions. 
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Figure 2.5 – The longest C-terminal construct (eEF-2K490-725) exists as a mixture of oligomeric and 
monomeric species. (A) Size exclusion traces of eEF-2K490-725 (CTD) show multiple species that are 
isolated during size exclusion chromatography with a Superdex200 10/300 column. The profile suggests 
that the C-terminal domain exists as a monomeric as well as soluble aggregate species. Re-injections of 
the void or monomeric fractions show similar profiles, suggesting that the CTD exchanges between these 
monomeric and soluble aggregate species. (B) SDS PAGE analysis of the size exclusion chromatography 
fractions confirm the presence of the CTD in all major peaks observed in the UV trace. 
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 Several truncated constructs of the C-terminal domain were generated to facilitate their structural 
analysis by NMR. Three C-terminal constructs, eEF-2K490-561, eEF-2K562-626, and eEF-2K627-725 were 
produced. While eEF-2K490-725 exhibits concentration dependent aggregation, eEF-2K562-621, eEF-2K627-725 
and eEF-2K562-725 are monomeric under conditions necessary for NMR analysis. NMR analysis of eEF-
2K562-621 suggests that it is disordered in solution, though eEF-2K627-725 and eEF-2K562-725 appear to be 
folded. We subsequently assigned and solved the structures of eEF-2K627-725 (Chapter 4)52 and eEF-
2K562-725 (manuscript in preparation; also see Chapter 5). 
Extensive efforts to find conditions in which eEF-2K490-725 exists as a homogenous monomeric 
species at concentrations suitable for NMR studies have so far been unsuccessful. Dynamic light 
scattering and size exclusion chromatography were used to screen buffer conditions in an attempt to 
identify buffer conditions under which this domain is monomeric at concentrations optimal for NMR 
analysis. Variable including pH (6.5 or 7.5), sodium chloride concentration (0 mM, 100 mM, 200 mM, 500 
mM), as well as addition of glycerol (1% and 5%) were screened. No conditions were found that 
completely prevented oligomerization of the C-terminal domain. Coupled with the fact that the C-terminal 
domain form a stable heterodimeric complex with the N-terminal constructs that include the KD, suggests 
that the interface responsible for this aggregation is buried or otherwise inaccessible in the context of the 
full-length protein. 
2.4 Cloning, Expression and Purification of Truncated Constructs of eEF-2K.  
SUMO-tagged N-terminal constructs of eEF-2K (eEF-2K1-358 or eEF-2K71-358) were cloned into a 
pET28a expression vector (Novagen) between the NdeI and HindIII restriction sites to generate His6-
SUMO tagged constructs and transformed into BL21 DE3 E. coli cells (New England Biolabs) for 
expression. The cells were plated on ampicillin plates and incubated overnight at 37 °C. SUMO-tagged C-
terminal domain constructs (eEF-2K490-725 and eEF-2K562-725) were similarly cloned into pET15b vector 
(Novagen) between the NdeI and BamHI restriction sites and transformed into BL21 DE3 E. coli cells 
(New England Biolabs) for expression. A single colony was inoculated into 10 mL of LB medium 
(containing 100 mg/L of ampicillin for C-terminal domain expression, 30mg/L kanamycin for Kinase 
domain expression, or 100 mg/L of ampicillin and 30mg/L kanamycin for co-expression of the two 
constructs) and grown overnight at 37 °C. The overnight culture was inoculated into 0.4 L of LB medium 
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and grown at 37 °C until the culture reached an A600 of 0.8, at which point the temperature was reduced to 
18 °C and expression was induced by the addition of IPTG to a final concentration of 0.4 mM. Post 
induction, the cells were grown for 16 hours and harvested by centrifugation at 2820 × g for 30 minutes.  
Unless otherwise stated, the cell pellet was re-suspended in 50 mL of cold lysis buffer (20 mM Tris, 
200mM NaCl, 0.1% β-mercaptoethanol, 0.1% Triton X-100, 10 mM imidazole and 1 tablet of Roche 
Complete Mini EDTA-free Inhibitor, at pH 7.5); all subsequent steps described below were carried out at 4 
°C. The cells were lysed by sonication and cell debris was removed by centrifugation at 10800 × g for 30 
minutes. The soluble lysate was added to a 5 mL (bed volume) Ni-NTA affinity column (Qiagen) 
previously equilibrated with lysis buffer and incubated for 1 hour with end-over-end rotation. The column 
was then washed extensively with washing buffer (20 mM Tris, 200 mM NaCl, 0.1% β-mercaptoethanol, 
20 mM imidazole, pH 7.5) and the bound protein was subsequently eluted with 50 mL of elution buffer (20 
mM Tris, 200mM NaCl, 0.1% β-mercaptoethanol, 250 mM imidazole, pH 7.5). The His6-SUMO tag was 
cleaved by the addition of ULP1 protease (1ug per 50 mL of elution) during overnight dialysis into 
cleavage buffer (20 mM Tris, 200 mM NaCl, 0.1% β–mercaptoethanol, pH 7.5). The effectiveness of 
cleavage was monitored by 12% SDS-PAGE gels. The purified protein was then concentrated using spin 
columns and further purified by gel filtration chromatography using a Superdex 200 10/300 GL (GE 
HealthCare Biosciences) column pre-equilibrated with a buffer containing 20 mM Tris, 200 mM NaCl, 2 
mM DTT.  
2.5 – Conclusions 
 It was found that the KD of eEF-2K could not be isolated in stable, soluble form when expressed 
in isolation in E. coli. However, co-expression of several KD-containing N-terminal constructs with multiple 
C-terminal domain constructs lead to solubilization, either as aggregates when using the shortest C-
terminal construct, eEF-2K562-725, or a stable heterodimeric complex when using the longer, eEF-2K490-725. 
In fact the KD co-expressed with eEF-2K562-725 could be retrieved in vitro from the soluble aggregates 
containing mixtures of eEF-2K1-358 and eEF-2K562-725 through incubation with eEF-2K490-725 forming a 
stable eEF-2K1-358•eEF-2K562-725 complex. The fact that each component of the latter complex were 
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separately expressed allows for differential isotope labeling of each component, thus simplifying NMR 
analyses.   
 
Chapter 3 – Overview of Biophysical Methods 
3.1 – Mass Spectrometry Methods 
3.1.1 – Native Mass Spectrometry  
 Native Mass spectrometry (Native MS) is an electrospray ionization based technique (ESI-MS) in 
which the protein or macromolecular assembly is interrogated under non-denaturing conditions.73–75 This 
method preserves the tertiary and quaternary structure of macromolecular assemblies, allowing the direct 
analysis of the stoichiometry of protein complexes.73–76 Once the sample is injected into the spectrometer, 
the droplets containing the protein or macromolecular complex shrinks as water and volatile buffer 
components dissociate. After desolvation, only the protein(s) and nonvolatile buffer components remain, 
the mass of which is subsequently determined.73–76 One limitation of this method is the requirement that a 
volatile buffer, typically ammonium acetate or ammonium bicarbonate, be used to reduce adduct 
formation during the desolvation process.77 However, low concentrations of non-volatile buffer 
components can typically be tolerated, especially if nanospray capillaries are used during electrospray 
ionization. 73,77 
 The charge state distribution from native MS has been shown to correlate to the solvent 
accessible surface area of a protein.78 An empirical formula has been developed to calculate the solvent 
accessible area of a protein using charge state analysis.78 Unfolded proteins or protein states that have a 
larger solvent accessible surface area are observed to display higher charge states compared to a more 
compact species.73,77,78 Therefore native MS can be used to assess the folding and aggregation state of a 
protein sample. 73–76,79 
3.1.2 – Hydrogen/Deuterium Exchange Mass Spectrometry 
 Hydrogen/deuterium mass spectrometry (HXMS) is a powerful tool that measures the exchange 
of labile protons for a protein or peptide.80–89 HXMS experiments are performed by incubating a protein in 
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a buffered D2O solution for defined lengths of time. During this incubation period, the exchangeable 
protons in the protein are gradually replaced with deuterium, resulting in a 1 Da increase in the mass of 
the protein per deuterium incorporated.80–89 Analysis of the resulting isotopic envelope can be used to 
determine the average mass of the species compared to the control sample and calculate the average 
number of hydrogen atoms exchanged for deuterium during the incubation.80–89 
The exchange rate of a labile proton within a folded protein is determined by multiple factors, 
including the intrinsic exchange rates of the residue, solvent exposure, and hydrogen bonding.80–89 The 
proton exchange rate is also pH sensitive. Backbone amides have a minimum exchange rate at a pH of 
~2.5.81,82,86,87,90 Therefore, acidifying the sample to a pH of ~2.5 and reducing the temperature can 
quench the exchange reaction of backbone amide protons.81,82,86,87,90 This allows the sample to be 
desalted and fractionated with chromatography methods such as reverse phase chromatography while 
preserving the deuteration state of backbone amides. Unfortunately, The N-terminus and labile side chain 
protons rapidly exchanged at this pH, resulting in loss of information about the exchange rates of these 
protons.81,88,91   
Uptake of deuterium by a protein can be determined for either the intact protein (intact mass 
HXMS) or fragmented proteins (local HXMS).80,81,92,82–89 Intact mass HXMS yields information about the 
deuterium uptake averaged over every residue within the protein. Thus global HXMS analysis provides 
information on whether different states of a protein are globally more or less dynamic i.e. have different 
average exchange rates.80,81,92,82–89 Intact mass HXMS is also useful for determining the incubation time 
ranges during which the proteins show moderate or rapid exchange and after which the protein becomes 
saturated with deuterium as well as optimizing experimental conditions for a particular system.82,87,91 
Because the global rate of exchange is the average of all exchangeable hydrogens within the protein, 
care must be taken when interpreting the data. For example, if ligand binding to a protein induces one 
region to become more dynamic and another to become equally more protected, the resulting increase 
and decreased in local exchange rates would be canceled out in the global analysis.82,89,90 Local HXMS 
can be used to identify these local changes in protection. 
Local HXMS differs from intact mass HXMS in that the protein is fragmented, allowing for analysis 
of the exchange rates for individual peptides within a protein.80–87,89 Fragmentation is generally achieved 
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either a proteolytic digestion (referred to as the bottom-up approach) or through gas-phase fragmentation 
after ionization within the spectrometer (top-down approach).93–95 The bottom-up approach fragments the 
protein after exchange and before injection into the mass spectrometer, which allows the resulting 
peptides to be isolated before mass determination (Figure 3.1).93–95 Identification of retention times for 
peptides from a reference sample facilitates the identification of the peptides from exchange 
experiments.90,91 Though the observed peptides are often several residues long, analysis of overlapping 
peptides allow exchange rates of smaller regions or even single residues to be determined (Chapter 5).90  
There are some limitations to HXMS experiments. Sufficient peptide coverage is critical for the 
analysis of HXMS data. Therefore finding conditions that yield enough assignable peptides is required for 
analysis of the regions of interest within a protein. 91,94 Factors such as residence time on the protease 
column and denaturants in the quench solution can be varied to optimize the proteolysis.90,91 The low 
temperature and pH required to quench the exchange reaction limits the commercially available 
proteases that can be utilized for these experiments. Pepsin, alone or in combination with fungal protease 
XIII, fungal protease XVIII or Plasmepsin 2, is commonly utilized due to their relatively non-specific 
proteolytic activity at low pH.96 “Back exchange” of the deuterium back to hydrogen during the proteolysis 
and chromatography steps is another factor that can complicate analysis of HXMS data.89–91 Though, 
comparison of two or more states and optimization of the chromatography protocol can generally 
circumvent these limitations. 
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Figure 3.1 - Schematic representation of a typical hydrogen deuterium exchange experiment. Both 
global and local HXMS exchange experiments are illustrated. First, the protein sample (S1) is diluted with 
D2O and incubated for a defined exchange time (S2). To stop the exchange, the sample is cooled on ice 
to ~4°C and quenched with a formic acid solution that reduces the pH of the sample to 2.4 (S3). The 
sample is then subjected to reverse phase chromatography before being injected directly into an ESI 
mass spectrometer. For local exchange, the protein is digested with an immobilized pepsin column before 
the chromatography steps. To reduce back exchange, the sample is always kept at ~4°C after quenching. 
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It is advantageous to compare relative exchange rates between different states of a biomolecule 
rather than absolute deutrium uptake.89–91,94 Relative uptake does not rely on exact determination of the 
back exchange, assuming the back exchange is the same for both states. Accurate correcting for back 
exchange requires a fully deuterated form of the protein, which can be technically challenging to prepare. 
Relative uptake measurements do not suffer from this difficulty because the back exchange generally is 
expected to be the same for both samples. Thus, the difference in deuterium uptake between two states 
is expected to be preserved despite low to moderate back exchange. Therefore comparing multiple states 
eliminates the requirement for precisely determining back exchange rates.82,91,94 
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3.1.3 – Chemical Crosslinking Mass Spectrometry 
Chemical crosslinking mass spectrometry can be used to identify interaction sites between two 
proteins. Chemical cross-linkers generate a covalent bond between specific protein residues.75,97–104 
Crosslinking reagents can be categorized by a variety of factors including functional groups that define 
what they react with, linker length, cleavability, and additional modifications such as affinity tags.103,105 For 
example, bis(sulfosuccinimidyl)suberate (BS3) contains two amine-reactive N-hydroxysulfosuccinimide 
(sulfo-NHS) esters (Figure 3.2A) separated by an 8-carbon spacer (yielding a maximum spacer arm 
length of 11.4 Å).104 The linker length defines the maximum length between the hydrodynamic radii of the 
two reactive groups.104,106 
A special class of these chemical modifiers are referred to as “zero-length” crosslinkers (Figure 
3.2B)103,105 include carbodiimides e.g. 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC).105 EDC 
catalyzes the peptide bond formation between carboxyl groups (aspartate or glutamate side chains and 
the C-terminus) to amine groups (lysine side chains or the N-terminus; Figure 3.2B). EDC first reacts with 
a carboxyl group to form a reactive, though relatively unstable, O-acylisourea intermediate (Step 1 in 
Figure 3.2B). N-hydroxysulfosuccinimide (sulfo-NHS) reacts with the O-acylisourea intermediate to yield a 
more stable sulfo-NHS ester intermediate (Step 2 in Figure 3.2B). The sulfo-NHS ester can then be 
attacked by an adjacent amine group, which results in amide bond formation between the carboxyl and 
amine group (Step 3 in Figure 3.2B). The reaction requires close proximity of the two side chains, thus 
reducing the maximum possible distance between two cross-linked residues.102 
Crosslinked proteins can be digested with specific proteases (such as trypsin, chymotrypsin, etc.) 
to generate peptides, which can then be analyzed by LC-MS.100,102,104 Software packages have been 
developed to search for crosslinked peptides within the resulting mass spectra.107,108 The suspected 
crosslinked peptides can then be validated by analysis of the fragmentation data as well as comparison to 
a reference sample.101 Chemical crosslinking allows identification of the interface between subunits within 
a complex and yields a sample of the interactions that occur in solution.  
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Figure 3.2 - Mechanism of Crosslinking Reactions. (A) The reaction between sulfo-NHS ester (such 
BS3) and the amine of a protein target is shown. In the case of BS3, the R group represents a four-
carbon linker attached to an identical sulfo-NHS ester at the other end. (B) The mechanism of the 
EDC/sulfo-NHS “zero length” crosslinking reaction is shown. Step 1 shows the reaction of EDC with a 
carboxyl group to form an O-acylisourea intermediate. In step 2, N-hydroxysulfosuccinimide (sulfo-NHS) 
reacts with the O-acylisourea intermediate to form a sulfo-NHS ester intermediate. The sulfo-NHS ester 
reacts with a primary amide group to form amine bond between the primary amine and the carboxyl 
groups. (Figure 3.2 was modified from Sinz, A. 2006)98 
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5.2 – NMR Methodology 
 Nuclear magnetic resonance (NMR) spectroscopy is commonly used to characterize the solution 
state structure and dynamic behavior of proteins. NMR is especially useful for structural characterization 
of macromolecular systems that are dynamic or otherwise difficult to crystalize. Additionally, NMR 
methods have been developed to interrogate the dynamic behavior of proteins and other biological 
molecules at time scales ranging from picosecond to seconds and beyond.109 Isotope enrichment 
methods as well as residue specific labeling schemes and ever improving pulse sequences have allowed 
analysis of increasingly complex systems. The purpose of this section is to provide a brief overview of the 
approaches used above. Many texts are available which provide in depth explanations of the methods 
and the underlying physics behind these phenomena.110–117 
5.2.1 – NMR Assignments 
 Utilizing complementary multidimensional heteronuclear NMR experiments is the most common 
approach for assigning protein chemical shifts, especially for large proteins.116,118 These experiments 
typically utilize one- or two-bond couplings to correlate the backbone amide H and N chemical shifts to 
the chemical shifts of the backbone and/or sidechain carbons.110,116,118 This approach has significantly 
improved upon previous methods especially for assigning larger proteins. Pulse sequences have been 
developed to determine the resonances of specific combinations of atoms within a residue or pair of 
sequential residues. For example, the CBCA(CO)NH experiment will report the Cα and Cβ chemical 
shifts of the (i-1) residue associated with backbone amide of the (i) residue.119 The HNCACB, on the other 
hand, reports the Cα and Cβ chemical shifts of both the (i) and (i-1) residue.120 By comparing the Cα 
and Cβ chemical shifts determined by these two experiments, it is possible to determine the sequential 
order of backbone amide 1H and 15N chemical shift pairs. Additionally, comparison of the observed 
chemical shifts to 13C chemical shift statistics of the Cα and Cβ carbons facilitates identification of the 
amino acid type. Comparison of the peptide sequences generated from this analysis to the sequence of 
the protein can then be used to unambiguously assign the observed chemical shifts to specific residues 
within the protein. Similarly, H(CCO)NH-TOCSY, (H)C(CO)NH-TOCSY, and HCCH-TOCSY can be used 
to assign chemical shifts for the remaining side chain positions as well as to resolve ambiguous backbone 
assignments.110,116,118 
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5.2.2 – Protein Structure Determination by NMR 
 While the generation of complete or near-complete chemical shift assignments of backbone and 
side chain positions represents the first step in the NMR analysis of proteins and protein complexes, 
additional constraints are necessary for the generation of structural models from NMR data.  Nuclear 
Overhauser effect (NOE) derived distance constraints are typically used in conjunction with chemical shift 
derived backbone dihedral angle constraints to generate structure models.111,121 Generally, these 
constraints are obtained from 13C and/or 15N-edited 3- and sometimes, 4-dimensional NOESY 
experiments to simplify spectral complexity and ease the semi-quantitative analysis of crosspeak 
intensities. In some cases, NOE-derived distance constraints are supplemented by orientational 
constraints derived from residual dipolar couplings (RDCs). These latter constraints often compensate for 
the lack sufficient long-range (> 4 residues) NOE-based distance constraints that are crucial in the 
determining the overall fold of the protein in question.118,122  
 As will be described in Chapters 4 and 5, we relied on both NMR-based as well as MS-based 
approaches to characterize the structure and interactions of eEF-2K.  
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Chapter 4 – Structure of the C‑Terminal Helical Repeat Domain of Eukaryotic Elongation Factor 2 
Kinase 
 
The contents of this chapter were published as: 
Will et al. Structure of the C-terminal helical repeat domain of eukaryotic elongation factor 2 
kinase. Biochemistry 55, 5377–5386 (2016) 
© 2016 American Chemical Society (reproduced with permission) 
 
3.1 – Abstract 
Eukaryotic elongation factor 2 kinase (eEF-2K) phosphorylates its only known physiological 
substrate, elongation factor 2 (eEF-2), which reduces the affinity of eEF-2 for the ribosome and results in 
an overall reduction in protein translation rates. The C-terminal region of eEF-2K, which is predicted to 
contain several SEL-1-like helical repeats (SLRs), is required for the phosphorylation of eEF-2. Using 
solution nuclear magnetic resonance methodology, we have determined the structure of a 99-residue 
fragment from the extreme C-terminus of eEF-2K (eEF-2K627−725) that encompasses a region previously 
suggested to be essential for eEF-2 phosphorylation. eEF-2K627−725 contains four helices, of which the first 
(αI) is flexible, and does not pack stably against the ordered helical core formed by the last three helices 
(αII−αIV). The helical core is structurally similar to members of the tetratricopeptide repeat (TPR) family 
that includes SLRs. The two penultimate helices, αII and αIII, comprise the TPR, and the last helix, α
IV, appears to have a capping function. The eEF-2K627−725 structure illustrates that the C-terminal deletion 
that was shown to abolish eEF-2 phosphorylation does so by destabilizing αIV and, therefore, the helical 
core. Indeed, mutation of two conserved C-terminal tyrosines (Y712A/Y713A) in eEF-2K previously 
shown to abolish eEF-2 phosphorylation leads to the unfolding of eEF-2K627−725. Preliminary functional 
analyses indicate that neither a peptide encoding a region deemed crucial for eEF-2 binding nor isolated 
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eEF-2K627−725 inhibits eEF-2 phosphorylation by full-length eEF-2K. Taken together, our data suggest that 
the extreme C-terminal region of eEF-2K, in isolation, does not provide a primary docking site for eEF-2. 
3.2 – Introduction 
Eukaryotic elongation factor 2 kinase (eEF-2K)29–31 (725 residues, 99 kDa) is a calmodulin-dependent 
member of the α-kinase family that regulates protein synthesis through phosphorylation of its only known 
cellular target, eukaryotic elongation factor 2 (eEF-2), on a specific threonine residue (T56). 29–34,58 This 
post-translational modification impedes the interaction between eEF-2 and the ribosome, thereby 
reducing global protein synthesis rates.18,32,33 The regulation of protein translation by eEF-2K is thought to 
be important in a host of physiological processes, including the regulation of cell cycle progression,65 
synaptic plasticity, learning, and the formation of memory.13,14,41 It has been suggested that eEF-2K, 
under conditions of nutrient deprivation, mediates an adaptive response in tumors, thus promoting tumor 
growth.5 The role of eEF-2K in the pathogenesis of cancer is further supported by several studies 
correlating eEF-2K expression with low survival rates in a variety of cancers such as glioblastomas, 
medulloblastomas,3 and breast cancer.25 Recent results suggest that eEF-2K plays a critical role in 
regulating the Warburg effect by modulating the synthesis of protein phosphatase 2A-A (PP2A-A).47 In 
addition, eEF-2K function has been implicated in a variety of neurological conditions such as Alzheimer’s 
disease123,124 and clinical depression125. Using a combination of deletions and site-directed mutagenesis 
supported by bioinformatic tools, previous studies have suggested a domain structure of eEF-2K49,51 
(Figure 4.1). eEF- 2K contains a sequence N-terminal to its catalytic kinase domain (KD) that takes part in 
a high-affinity interaction with Ca2+-loaded calmodulin (CaM).53 This interaction initiates a conformational 
change allowing the efficient autophosphorylation of a specific threonine (T348, dark green in Figure 4.1) 
located on a regulatory loop (R-loop) C-terminal to the KD. A subsequent interaction involving the 
phosphorylated T348 and the KD leads to a further conformational change, resulting in the fully active 
state of the kinase.37 The eEF-2K KD bears significant sequence homology with the catalytic domains of 
other α-kinases, e.g., the ion-channel kinase TRPM7 (28% identity)126 and myosin heavy chain kinase A 
(MHCK-A, 34% identity) from Dictyostelium discoideum59. In addition to T348, the R-loop, which is 
predicted to be disordered, contains other phosphorylation sites that lead to negative (red in Figure 4.1) 
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or positive (green in Figure 4.1) regulation12 of kinase activity. The C-terminal region/domain (CTD) of 
eEF-2Ks predicted to contain several SEL-1-like helical repeats (SLRs), a structural motif that is known to 
provide a platform for protein−protein interactions.60 This region, which is essential for the physiological 
function of eEF-2K both in modulating kinase activity and in recognizing substrate,48 shows poor 
homology with sequences for which structural information is available. The CTD has been shown to 
regulate the activity of eEF-2K, and it has been suggested that this occurs through a direct interaction 
with the KD.48 It has been further shown that an eEF-2K construct (336−725, which excludes the N-
terminal CBD and the KD but includes the R-loop and the entire CTD) can be coprecipitated with eEF-2, 
suggesting that this region contains the binding site for eEF-2.51 Deletion of the extreme C-terminus 
(residues 711−725) of eEF-2K results in the loss of kinase activity against eEF-2 but not against a peptide 
substrate, MH-1, leading to the suggestion that this region plays a role in recognizing eEF-2.48 Given the 
fact that the structure of intact full-length eEF-2K is not yet available, we undertook the characterization of 
the structural elements comprising the CTD using solution nuclear magnetic resonance (NMR) 
spectroscopy. The rationale behind this choice is twofold. (1) While a model for the KD has been derived 
using the structures of TRPM7 and MHCKA as templates and this model has proven to be robust for the 
analysis of small molecule functional modulators,127,128 the poor similarity of the CTD sequence with those 
of known structure makes homology modeling difficult. (2) A structure of the CTD or of relevant fragments 
thereof should provide a basis for deciphering the nature of the interaction between the CTD and the KD 
and indeed with the substrate, eEF-2. 
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Figure 4.1. Schematic representation of the domain structure of eEF-2K. The N-terminal calmodulin-
binding domain (CBD), catalytic kinase domain (KD) and the C-terminal domain (CTD) are shown. The 
region between the KD and CTD is known as the regulatory loop (R-loop) that contains both upregulating 
(green) and downregulating (red) phosphorylation sites. The kinases that target these phosphorylation 
sites are indicated. The N-terminal S78 can act as both an activating as well as an inhibitory site. T348, 
the autophosphorylation of which constitutes a key step in the activation eEF-2K is shown in dark green. 
The specific C-terminal mutations, discussed in the text that either reduce (red) or enhance (green) eEF-2 
phosphorylation, are indicated. The lower panel shows the location of the PFAM-predicted SEL-1 like 
repeats (SLRs). The eEF-2K627-725 construct (shaded light blue, 627-725) includes the last two predicted 
SLRs. 
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 As a first step toward this goal, we obtained the solution structure of a 99-residue C-terminal 
fragment of eEF-2K (residues 627−725, denoted eEF-2K627−725) that encodes the final two SLRs predicted 
by an analysis of the eEF-2K sequence against the PFAM database129 (Figure 4.1). This construct 
includes the region (residues 711−718) that has been suggested to be required for the phosphorylation of 
eEF-2.48 The structure of eEF-2K627−725, presented here, along with our recent structure of the eEF-2K 
CBD in complex with Ca2+/ CaM,53 represents the first high-resolution structural information for the 
unique enzyme that is eEF-2K. Our data provide a structural framework for interpreting the effects of the 
deletions and/or mutations at the C-terminus of eEF-2K that impede its ability to phosphorylate eEF-2.48 
These data, in combination with preliminary competition assays presented here, suggest that this loss of 
activity toward eEF-2 is the result of structural destabilization of eEF-2K resulting from the delections 
and/or mutations rather than a loss of the primary binding site for eEF- 2 that does not appear to be 
contained uniquely within the isolated eEF-2K627−725 fragment. 
3.3 - Materials and Methods 
3.3.1 - Protein Expression and Purification 
The C-terminal fragment of eEF-2K (S627−E725, 99 residues, eEF-2K627−725) was cloned into a 
pET15b expression vector (Novagen) between the NdeI and BamHI restriction sites and transformed into 
BL21 DE3 cells (New England Biolabs) for expression. The cells were plated on ampicillin plates and 
incubated overnight at 37 °C. A single colony was inoculated into 10 mL of M9 minimal medium and 
grown overnight at 37 °C. After centrifugation at 4 °C and 4000g for 20 min, the cells from the starter 
culture were inoculated into 0.5 L of M9 minimal medium containing 1 g of 15N-labeled ammonium 
chloride and 2g of 13C-labeled glucose as the sole nitrogen and carbon sources, respectively. The cells 
were grown at 37 °C until the culture reached an OD600 of 0.8, at which point the temperature was 
reduced to 18 ° C and expression was induced by addition of 0.4 mM isopropyl β -D-1-
thiogalactopyranoside (IPTG). Cells were subsequently grown for 20 h and harvested by centrifugation at 
4 °C and 3000g for 30 min. Harvested cell pellets were resuspended in 40 mL of lysis buffer [20 mM 
Tris, 0.1% β-mercaptoethanol, 10 mM imidazole, and 1 tablet of Roche Complete Mini EDTA-free 
inhibitor (pH 7.5)]; all subsequent steps described below were performed at 4 °C. The cells were lysed 
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by sonication, and cell debris was removed by centrifugation at 4 °C and 15550g for 30 min. The soluble 
lysate was added to a 3 mL (bed volume) Ni-NTA affinity column (Qiagen) previously equilibrated with 
lysis buffer and incubated for 1 h on a rotary agitator. The column was then washed extensively with 
washing buffer [20 mM Tris, 0.1% β - mercaptoethanol, and 20 mM imidazole (pH 7.5)], and 
subsequently, the bound protein was eluted with 50 mL of elution buffer [20 mM Tris, 0.1% β -
mercaptoethanol, and 250 mM imidazole (pH 7.5)]. The N-terminal His6 tag was cleaved with the addition 
of ∼50 units of human α-thrombin (Enzyme Research Laboratories) while being dialyzed overnight into 
cleavage buffer [20 mM Tris, 0.1% β-mercaptoethanol, and 5 mM EDTA (pH 7.5)]. The effectiveness of 
cleavage was monitored by 15% sodium dodecyl sulfate−polyacrylamide gel electrophoresis 
(SDS−PAGE) gels. The cleavage reaction was quenched by the addition of 0.1 mM AEBSF (Sigma-
Aldrich). The protein was then concentrated using spin columns and further purified by gel-filtration 
chromatography using a Superdex 75 10/300 GL (GE HealthCare Biosciences) column pre-equilibrated 
with NMR buffer [50 mM phosphate and 4 mM DTT (pH 6.5)]. Fractions containing pure eEF-2K627−725 
were collected and concentrated using a spin column to final concentrations ranging from 300 to 600 μM 
for NMR experiments. 
The Y712A/Y713A, Y712A, Y713A, and E717A mutants of eEF-2K627−725 were generated using 
the QuikChange Multi Site-Directed Mutagenesis Kit (Agilent) and appropriately designed primers. The 
mutated plasmid was transformed into XL10-Gold ultracompetent Escherichia coli cells supplied with the 
kit. For protein expression, Y712A/Y713A and E717A constructs were transformed into BL21 DE3 cells 
and expressed using the protocol described above for wild-type eEF-2K627−725. The Y713A mutant was 
expressed at 37 °C for 4 h after IPTG induction. The Y712A construct did not express under any of the 
conditions tried. The purification protocol for all of the mutants was the same as that used for the wild-
type protein, as described above. 
3.3.2 - Resonance Assignment 
All NMR experiments were conducted at 25 °C using Varian Inova (600 MHz) or Bruker Avance 
spectrometers (600, 700, and 800 MHz) equipped with cryogenic probes capable of applying pulsed-field 
gradients along the z-axis. All NMR data were processed and analyzed using the NMRPipe130 and 
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NMRViewJ131 software suites, respectively. Backbone resonance assignments were obtained using 
standard backbone-directed triple-resonance strategies116 using HNCO/HN(CA)CO and 
HNCACB/CBCA(CO)NH pairs. Side chain resonance assignments were obtained though H(CCO)NH-
TOCSY, (H)C(CO)NH-TOCSY, and HCCH- TOCSY.116 Details of these experiments are provided in 
Table 4.1. Distance constraints were obtained from three-dimensional (3D) 15N-edited NOESY-HSQC, 
13C-aliphatic edited, and 13C-aromatic NOESY-HSQC experiments, using mixing times of 150 ms in all 
cases. Aromatic assignments were obtained via 13C-aromatic edited NOESY-HSQC supplemented with a 
two- dimensional (2D) 1H−1H NOESY experiment. 13C-aliphatic edited and homonuclear NOESY 
experiments were performed in D2O-based buffers. Experimental details of the NOESY experiments are 
provided in Table 4.2. Methionine ε-methyl groups were assigned using the NOESY experiments in 
combination with 3D HMBC and 3D LRCH experiments132 (see Table 4.1 for details). The assigned 
chemical shifts have been deposited in the BMRB as entry 30135. Measurement of Residual Dipolar 
Couplings. Partially oriented samples for residual dipolar coupling (RDC) measurements were obtained 
by adding Pf1 phage (ASLA Ltd.)119 directly to the NMR sample (the pH was manually adjusted to 6.5) for 
a final concentration of 15 mg/mL phage and 300 μM eEF-2K627−725. Amide 15N−1H RDCs were collected 
at 600 MHz using 2D 15N IPAP122 pulse sequences (spectral windows of 12 and 28 ppm with 512 and 128 
complex points in the direct and indirect dimensions, respectively) on both aligned (2H quadrupolar 
splitting of ≈23 Hz) and isotropic samples. The measured RDCs were analyzed using the PALES software 
suite133 and utilizing the initial structural ensemble generated using distance and dihedral angle 
constraints only. 
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Table 4.1. Parameters for Backbone and Sidechain Assignment Experiments 
Experiment 
Point
s 
SW 
Nucleu
s 
Point
s 
SW 
Nucleu
s 
Point
s 
SW 
Nucleu
s 
Fiel
d 
HNCO 512 13 1H 28 10 13C 28 26 15N 600 
HN(CA)CO 512 13 1H 28 10 13C 28 26 15N 600 
CBCA(CO)NH 512 13 1H 48 10 13C 28 26 15N 600 
HNCACB 512 13 1H 48 10 13C 28 26 15N 600 
H(CC)(CO)NH
-TOCSY 
512 13.3 1H 80 26 15N 28 11 1H 600 
(H)CC(CO)NH
-TOCSY 
512 13.3 1H 80 26 13C 29 
43.
7 
15N 600 
HCCH-TOCSY 512 
13.3
5 
1H 32 32 13C 40 13 13C 800 
3D-HMBC 512 10.0 1H 8 4.0 13C 128 
18.
0 
13C 700 
3D-LRCH 512 10.0 1H 8 4.0 13C 128 
7.4
0 
1H 700 
 
Fields are in MHz, points are complex points and sweep-widths (SW) are in ppm. All experiments were 
performed at 25 °C in H2O, with the exception of the HCCH-TOCSY, that was collected in a D2O-based 
buffer. 
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Table 4.2. Parameters for 2D and 3D NOESY Experiments 
Experime
nt 
Point
s 
SW Nucleu
s 
Point
s 
SW Nucleu
s 
Point
s 
SW Nucleu
s 
Mixin
g 
Time 
Fiel
d 
15N,1H 
NOESY-
HSQC 
1024 11.
6 
1H 64 26 15N 224 11.
6 
1H 120  800 
13Caromatic 
NOESY-
HSQC 
1024 10 1H 54 28 13C 128 10 1H 150  700 
13Caliphatic 
NOESY-
HSQC 
1024 11 1H 64 61 13C 128 11 1H 150  600 
1H,1H 
NOESY  
4096 13.
9 
1H 512 13.
9 
1H - - - 150  800 
 
The 15N-edited NOESY and the 13Caromatic-edited NOESY experiments were recorded in H2O-based 
buffers, the 13Caliphatic-edited and the 2D NOESY experiments were performed in D2O-based buffers. 
Mixing times are in ms. 
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3.3.3 - Relaxation Measurements. 
15N longitudinal (R1) and transverse (R2) relaxation rates were obtained at 600 MHz using 
standard pulse sequences.110 The following relaxation delays were used: 10, 50, 100, 200 (twice), 400, 
500, 700, and 900 ms (twice) for R1 and 0.0, 17 (twice), 34, 51, 68, 85, 102 (twice), 136, 170, and 203 ms 
for R2. Steady-state {1H}−15N nuclear Overhauser effect (NOE) experiments were also performed at 600 
MHz using the pulse sequence of Ferrage et al.134 using a saturation time of 5 s and an overall delay of 7 
s. All relaxation experiments used sweep widths of 12 and 28 ppm with 512 and 128 complex points in 
the direct and indirect dimensions, respectively. 
3.3.4 - Structure Calculations 
Structure calculations were performed using ARIA2.3 (CNS1.2) following published protocols.135 
Briefly, TALOS+136 was used to obtain dihedral angle constraints from chemical shifts (1H, 1Hα, 13Cα, 
13Cβ, 13C, and 15N), and peak intensities of the 3D NOESY experiments were introduced directly into 
ARIA to derive ambiguous distance restraints. Spin-diffusion correction was introduced for all NOESY 
spectra.137 The required correlation time was estimated using the measured 15N relaxation rates for the 
structured parts of the protein. 
Structure calculations were performed within the standard ARIA protocol using PROLSQ138 for 
nonbonded parameters; 20000 and 40000 steps were used for the high-temperature (10000 K) torsion 
angle simulated annealing (27 fs integration time) and the two Cartesian cooling phases (1000 K, 50 K as 
the final temperatures, 3 fs integration time), respectively. Network anchoring was introduced into the first 
three iterations of the protocol, and floating chirality was implemented for the prochiral moieties. A log-
harmonic potential139 and the automatic restraints weight protocol were implemented during the second 
cooling phase. During this stage, the weight for the dihedral restraints was reduced to 5, and hydrogen 
bond restraints were introduced for those residues predicted by TALOS+136 to be in a helical 
conformation. RDCs for the helical fragments (excluding those from α I, residues 634−637) were 
introduced as intervector projection angle restraints140 using the dipolar_segid.py script from the 
HADDOCK software suite.141 The alignment tensor components necessary for the conversion were 
estimated using PALES133 and the measured RDC values on a preliminary NMR structural ensemble 
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obtained without RDC restraints. Those angular restraints limiting the torsional space by >25% were 
introduced in the ARIA calculations starting from the fifth iteration. Of the 400 structures generated in this 
way, 179 were refined with 24000 steps of a Cartesian dynamics protocol in explicit water.142 Unless 
specifically mentioned, default values were used for all ARIA input variables. The final structures were 
analyzed using PRO-CHECK-NMR 2.0143 and the WHATIF Web server.144 Structures in the NMR 
ensemble were aligned using the McLachlan algorithm as implemented in PROFIT version 3.1 and 
visualized using open-source PyMOL version 1.7.6. The NMR ensemble has been deposited into the 
Protein Data Bank (PDB) as entry 5KS5. 
3.3.5 - Competition Assays 
For the competition assays described below, eEF-2K was expressed and purified using protocols 
described previously.36 Established procedures were utilized to purify wheat germ eEF-2145 and yeast 
eEF-2,146 for use in the peptide and eEF-2K627−725 inhibition assays, respectively. Wheat germ eEF-2147,148 
and yeast eEF-2149 have been shown to be phosphorylated by mammalian eEF-2Ks with kinetic 
parameters similar to the values of those derived from mammalian cells. 
Competition assays were performed at 30 °C in buffer B [25 mM HEPES (pH 7.6), 2 mM DTT, 10 
μg/mL BSA, 10 mM MgCl2, 100 μM EGTA, 150 μM CaCl2, and 2 μM CaM] at pH 7.6. For each 
reaction, 10 μM eEF-2 was incubated with either 0 (25 mM HEPES) or 500 μM C-terminal peptide 
(acetyl-707RLANQYYQKAEEAWAQMEE725-amide) for 30 min at 30 °C followed by incubation with 0.5 
nM eEF-2K for an additional 10 min. The reaction was initiated by the addition of 1 mM [γ-32P] ATP 
(100−1000 cpm/pmol) in a total volume of 100 μL. At set time points (60, 120, 180, 240, 300, and 360 s), 
10 μL aliquots were taken and spotted onto P81 cellulose filters (Whatman, 2 cm × 2 cm). The filter 
papers were then washed thrice in 50 mM phosphoric acid (15 min each wash) and once in acetone (15 
min) and finally dried. The amount of labeled peptide associated with each paper was determined by 
measuring the counts per minute on a Packard 1500 scintillation counter. All experiments were performed 
in duplicate. 
To test inhibition of eEF-2 phosphorylation by eEF- 2K627−725, eEF-2K (final concentration of 0.2 
nM) was added to buffer B (pH 7.5, 6 μM eEF-2) containing either eEF- 2K627−725 (20 μM) or an 
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equivalent volume of buffer and equilibrated at 27 °C for 3 min, followed by initiation with 1 mM [γ-32P] 
ATP, as described above. The reaction was allowed to proceed for 5 min, at which time 10 μL was 
removed, added to quench buffer (5× SDS−PAGE buffer with 50 mM EDTA), and boiled for 5 min. 
Quenched samples were subjected to SDS−PAGE analyses, and autoradiography images were acquired 
using a Typhoon phosphorimager. Quantification of eEF-2 band intensities in the autoradiographs, 
reported as arbitrary units, was conducted in ImageJ150 after first linearizing the .gel file with the “Linearize 
GelData” plug-in (https:// imagej.nih.gov/ij/plugins/linearize-gel-data.html). Additional quantification of 
phosphate incorporated into eEF-2 was performed by scintillation counting of the excised eEF-2 bands 
from the SDS−PAGE gel, using the specific activity of [γ-32P] ATP and the amount of eEF-2 per lane (60 
pmol) to calculate the phosphate/eEF-2 molar ratio. 
3.4 - Results and Discussion: 
3.4.1 - Choice of the eEF-2K627−725 Construct 
It has been previously reported, on the basis of sequence analysis, that the CTD of eEF-2K is 
highly α-helical and is predicted to contain several SLRs.48,51 To isolate, express, and structurally 
characterize this region, we first attempted to localize the domain structure of the region by analyzing the 
D473−E725 fragment of eEF-2K using bioinformatics tools. An analysis of the eEF-2K sequence against 
the PFAM database129 leads to the prediction of four SEL-1-like repeats (SLRs): L528−G562, 
T590−D609, E636−M647, and A672−A699. Combining this prediction with the results of the GeneSilico 
metaserver151 to identify secondary structural elements and disordered regions, we designed the eEF-
2K627−725 construct to include the last two SLRs and the extreme C-terminus that has been shown to be 
required for the phosphorylation of eEF-2.48 
3.4.2 - Resonance Assignment of eEF-2K627−725. 
The 15N−1H HSQC spectrum of eEF-2K627−725 (Figure 4.2) shows dispersion that is characteristic 
of high α-helical content and suggests the presence of well-ordered regions. Using standard backbone-
directed triple-resonance experiments (see Table 4.1), we were able to assign all of the main chain amide 
15N, 1H, 1Hα, 13Cα, and 13C′ resonances for non-proline residues (excluding the four additional amino 
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acids remaining after thrombin cleavage). For the three prolines, all the 1Hα, 13Cα, and 13C’ resonances 
could be assigned. Additionally, we obtained assignments for 100% and 99.5% of side chain 1H and 13C 
resonances, respectively; 92.4% and 84.3% of aromatic 1H and heteronuclear resonances, respectively, 
were also assigned, and 88.9% and 84.2% of 1H and 15N atoms belonging to the amino side chains of 
Asn and Gln could be assigned, respectively. These assignments were then utilized to obtain distance 
constraints from a variety of NOESY (Table 4.2) data sets and combined with chemical shift-based 
backbone dihedral angle constraints using TALOS+136 and 15N−1H RDCs to determine the structure of 
eEF-2K627−725. 
3.4.3 - Solution Structure of eEF-2K627−725. 
As expected from chemical shift analysis, eEF-2K627−725 contains four helical segments. The structural 
ensemble (Figure 4.3) confirms that these helical elements are localized to the regions encompassing (in 
at least 90% of the structures comprising the NMR ensemble) W634−A637 (αI), R664−T677 (αII), 
P686−E702 (αIII), and G706−Q722 (αIV). While helix αI comprises a single helical turn in all structures 
of the NMR ensemble, this helical segment extends from D633 to W640 in ∼60% of the structures, 
suggesting significant disorder at the extremities. Indeed, this helix appears to be more dynamic and 
structurally ill-defined than the others (see below). In contrast, the last three helices are ordered and fold 
into an antiparallel helical bundle, where individual helices (αII−αIV) stack sequentially on each other 
and form an elongated shape centered on αIII. The overall fold is stabilized by a number of van der 
Waals contacts involving contiguous helices, specifically between αII (involving residues Y665, L668, 
A669, E671, A672, E673, L675, and F676) and αIII (R688, S689, L692, Y693, Q695, A696, A699, A700, 
and A703) and between αIII (P686, Q687, G690, D691, Y693, T694, A696, A697, A700, and M701) and 
αIV (L708, A709, Y712, Y713, K715, A716, A719, and W720). All of the listed residues participate in 
multiple contacts, each detectable in at least 90% of the structures that comprise the NMR ensemble. 
Further, a subset of these residues, namely, Y665, A669, and F676 on αII, Y693, A696, and A700 on α
III, and Y712 and A719 on αIV, stabilize the helical core by forming simultaneous contacts with both of 
the other two helices of the bundle (Figure 4.4). 
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Figure 4.2. Assigned 15N, 1H HSQC spectrum of eEF-2K627-725 (600 MHz). Sidechain resonances are 
labeled in red. Data were collected in a buffer containing 50 mM phosphate, 4 mM DTT at pH 6.5. 
Experiments were performed at 25 °C. 
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Figure 4.3. Structure of eEF-2K627−725. (A) The NMR ensemble consisting of the 20 lowest energy 
structures overlaid on helices αII, αIII and αIV (using backbone heavy atoms). (B) Ribbon representation 
of the lowest energy structure showing the location of the four helices. The helices (αII-αIV) that comprise 
the helical core are shown in red and the N-terminal helix (αI) is shown in blue. Loops are shown in 
green. 
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 As expected, from the root-mean-square deviation (RMSD values for the structures that comprise 
the NMR ensemble (Table 4.3), the last three helices (αII−αIV) are largely ordered, displaying large 
values for the reduced spectral density function at zero frequency, J(0) (2.6 ± 0.4 ns/rad), and small 
values at high frequency, J(0.87ωH) (7.0 ± 1.3 ps/rad) (see Figure 4.5). The compactness of the tertiary 
fold involving helices αII−αIV is the consequence of a large number (168) of long-range (≥i, i + 5) 
contacts that leads to small pairwise rmsds among the structures (see Table 4.3) that constitute the NMR 
ensemble. In contrast, this network of long-range contacts is missing for αI, and as a result, it assumes a 
variety of different orientations with respect to the helical bundle in the NMR ensemble (Figure 4.3). That 
this is indeed a true feature of this region of eEF-2K627−725 rather than an inadequacy in the NOE 
assignment or in the structure calculation protocol is reinforced by the fact that the order parameters 
predicted from the chemical shifts [RCI S2, (Figure 4.6A)]152 are lower for helix αI (0.73 ± 0.05) than for 
the helical core comprising αII−αIV (0.87 ± 0.06). Additionally, αI is characterized by a J(0) (2.0 ± 0.3 
ns/rad) lower than, and a J(0.87ωH) (12.7 ± 1.4 ps/rad) significantly higher than those of the αII−αIV 
core, indicating a larger amount of disorder on the fast time scale (Figure 4.5). A plot of J(ωN) versus J(0) 
shows that αI occupies a region distinct from the remaining helices (Figure 4.7). Further, while the amide 
15N−1H RDC values for the helical bundle (αII−αIV) tend to be negative in sign and are generally quite 
large in overall magnitude [−19 ± 10 Hz, (Figure 4.6B)], for helix αI, the RDC values range from −1.2 to 
2.4 Hz and are not dissimilar from those observed in the contiguous, mostly unstructured Y641−Q660 
loop (RDC = 1.6 ± 1.3 Hz). The RDC and relaxation data combined strongly suggest that αI is not 
anchored to the helical core comprised of αII−αIV. This disorder is largely facilitated by the highly 
dynamic nature of the αI−αII loop encompassing Y641−Q660 [J(0.87ωH) = 18.4 ± 3.5 ps/rad], and 
indeed in the structures of the NMR ensemble, this region does not converge around a unique fold 
(Figure 4.3). A statistical analysis of the secondary structure elements, however, indicates a propensity 
for various turn like conformations in this area, as suggested by the presence of several medium-range 
NOEs. 
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Figure 4.4. Structure of the helical core, comprising helices α II-α IV. Residues that make key inter-
helical contacts are shown as sticks. Residues that stabilize the core by making contacts involving all 
three helices are shown and labeled in red; other colors indicate helix-helix contacts as shown in the key. 
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Table 4.3. Refinement and structure statistics for eEF-2K627-725 
 
Pairwise Cartesian RMS deviation (Å) 
 All Core 
Global backbone heavy atoms 3.92 ± 2.12 0.93 ± 0.32 
Global heavy atoms 4.56 ± 1.85 1.79 ± 0.32 
Ordered backbone heavy atoms 1.18 ± 0.37 0.42 ± 0.10 
Ordered heavy atoms 2.08 ± 0.41 1.41 ± 0.16 
   Restraint information 
   NOEs: Intra-residue 530 365 
NOEs: Sequential (Δ=|i-j|=1) 317 205 
NOEs: Medium (5 > Δ=|i-j| ≥2) 221 174 
NOEs: Long (Δ=|i-j| ≥5) 183 168 
Dihedral angle restraints (φ, ψ) 122 98 
Inter-vector projection angle restraints  565 565 
Hydrogen Bonds Restraints 70 68 
   Energies, NOE Statistics 
Total (KCal•mol-1) -4313.72 ± 68.92 
Electrostatic (KCal•mol-1) -4192.93 ± 70.1 
van Der Waals (KCal•mol-1) -895.07 ± 10.1 
   Conformers NOEs RMS (Å) 0.167 ± 0.037 
   Ramachandran statistics (%) 
   Most favored regions 82.2 90.9 
Additionally allowed regions 15.6 7.3 
Generously allowed regions 1.1 1.8 
Disallowed regions 1.1 0 
   Average RMS Z-scores for deviation from current reliable structures 
   Bond lengths  0.22 ± 0.01 0.20 ± 0.01 
Bond angles  0.38 ± 0.01 0.33 ± 0.02 
Omega angle restraints (°) 0.59 ± 0.04 0.56 ± 0.06 
Side-chain planarity  0.43 ± 0.12 0.46 ± 0.17 
Improper dihedral distribution 0.45 ± 0.09 0.47 ± 0.13 
Inside/Outside distribution 1.16 ± 0.03 1.06 ± 0.02 
   Average RMS Z-scores for deviation from current reliable structures 
   1st generation packing quality -2.48 ± 0.15 -0.56 ± 0.18 
2nd generation packing quality -2.84 ± 0.38 -0.87 ± 0.39 
χ1/χ2 rotamer normality -1.75 ± 0.73 -1.19 ± 0.69 
Backbone conformation -0.86 ± 0.35 1.61 ± 0.25 
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Figure 4.5. Spectral Density function of eEF-2K627−725. Reduced spectral density functions at 0 (A), ωN 
(B) and 0.87ωH (C) frequencies calculated from backbone 15N relaxation data measured at 600 MHz and 
25 °C are plotted against residue number. 
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Figure 4.6. Random Coil Index of eEF-2K627−725. Random Coil Index (RCI) derived S2 values (A) and 
15N-1H residual dipolar couplings (RDCs) (B) measured using Pf1 phage for the eEF-2K627-725 construct 
are plotted against residue number. 
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Figure 4.7. Plot of the spectral density function at the 15N frequency, J(ωN) against that at zero 
frequency, J(0). The colored spheres represent data from specific regions of eEF-2K627-725 as follows – 
green: αII, αIII, αIV and the αIII-αIV loop; red: αI; cyan: αII-αIII loop; yellow: αI-αII loop; blue: extreme N- 
and C-termini. The curve represents the limiting case where the protein is rigid without any internal 
dynamics and molecular tumbling is characterized by a single correlation time (isotropic diffusion). Data 
were collected at 600 MHz. 
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3.4.4 - Similarities with Known Structural Families. 
SLRs, together with the tetratricopeptide repeats (TPR) and the pentatricopeptide repeats (PPR), 
form a class of proteins called solenoids.153 Solenoids are comprised of basic repeating helix 
(A)−turn−helix (B) motifs that stack onto each other forming a superhelical assembly driven largely by van 
der Waals interactions connecting the second (B) and, to a lesser extent, the first (A) helix of a given 
structural unit to the first helix (A’) belonging to the following repeat.154,155 The structurally related SLR, 
TPR, and PPR motifs60 differ only slightly in their characteristic consensus sequences. In fact, SLR motifs 
are considered to be a subclass of TPR motifs.60 Compared to TPRs, SLRs are characterized by longer 
loops between the two helices comprising the individual motifs and shorter loops connecting different 
repeat units. The consensus sequences themselves, however, are loosely defined for TPRs and SLRs 
alike, as they require few specific residues to be conserved, preferring instead broad classes of side 
chains (small, large, hydrophobic, etc.) for the individual positions, and in fact, few positions are truly 
invariant156 (Figure 4.8). As a consequence, accurate sequence-based prediction of such entities in a 
protein of unknown structure can be challenging.157 Indeed, on the basis of the structure of eEF-2K627−725, 
the length of the loop between αII and αIII (nine amino acids) is more consistent with an SLR rather 
than a TPR. However, a query to the DALI server158,159 for structures in the PDB homologous to eEF- 
2K627−725 produces matches with a large number of motifs belonging to the TPR family but not the SLR 
subfamily. While there is little difference between the structures of the individual repeats between the 
canonical TPR and SLR motifs, the largest difference lies in their super helical parameters (resulting from 
the arrangement of multiple repeats), with the former being narrower than the latter.60 Therefore, whether 
eEF-2K627−725 indeed conforms to a TPR motif or to an SLR motif can be confirmed only once the 
structure of the intact CTD is available. 
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Figure 4.8. Comparison of eEF-2K627−725 to TPR and SLR consensus motif. Sequence preferences for 
the TPR and SLR consensus motifs (80% confidence) from SMART. Also shown at the bottom is the 
sequence comprising the αII and αIII helices in eEF-2K627-725. Compare Figure 6 in the main text.  
The SMART consensus group of residue types are as follows: 
l (aliphatic): I, L, V 
. (any) 
a (aromatic): F, H, W, Y 
h (hydrophobic): A, C, F, G, H, I, K, L, M, R, T, V, W, Y 
p (polar): C, D, E, H, K, N, Q, R, S, T 
s (small): A, C, D, G, N, P, S, T, V 
u (tiny): A, G, S 
t (turn-like): A, C, D, E, G, H, K, N, Q, R, S, T 
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Superhelices of the TPR family often terminate with a single helical motif, termed the capping or 
solubility helix that stabilizes the sequence. Upon analysis of the 10 best nonredundant entries that 
resulted from the DALI query (see Table 4.4), we noted two distinct sets of patterns for the alignments 
(Figure 4.9 and Table 4.4). In some of the cases, the αII−αIV helical core of eEF-2K627−725 aligns best 
with a C- terminal repeat, with αIV aligning with the corresponding C- terminal capping helix. In others, 
αII and αIII structurally align with a particular TPR hairpin in the matching protein while αIV aligns with 
the (A) helix belonging to the following repeat module. Obviously, the first scenario appears to be the 
more appropriate, given the C-terminal location of the eEF-2K627−725 fragment. 
A structural alignment with an idealized TPR sequence is of interest because it allows the 
comparison of side chain packing observed for eEF-2K627−725 to that of a structure derived from the 
consensus sequence (Figure 4.10). Of the seven signature residues identified in the hairpin motif (in 
addition to one in the intervening loop) by Main and co-workers,155 two are fully conserved (Y693 and 
A696) and three other positions are compatible with the SMART160,161 consensus requirements (L668/W, 
A672/G, L675/Y, and S689/A). The only side chain that appears to diverge from both the SMART and the 
signature residue is found at position 671 (E671/L). In the idealized TPR structure, the signature residues 
in a given helix form contacts with the complementary helix within the same hairpin, and with helices from 
the neighboring repeats. E671 on αII is indeed involved in van der Waals interactions with αIII residues. 
According to the TPR global propensities calculated by Main et al.,155 the leucine residue in this position 
(7 in their work, 10 in Figure 4.10A) has a propensity value much lower than those of the other signature 
residues. The second highest propensity value for this side chain is an arginine, suggesting that charged 
residues are tolerated at this position. 
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Table 4.4. Structural Homologs of eEF-2K627-725 
Count PDB ID CHAIN Z RMSD % Identity DESCRIPTION 
1 2XCB A 9.7 1.2 16 Regulatory protein PCRH 
2 5A6C B 9.4 1.3 5 G-protein-signaling modulator 2, Afadin 
3 4A1S A 9.1 1.2 7 Partner of Inscuteable  
4 2VKJ A 8.7 1.3 13 TM1634 
5 1QQE A 8.3 1.1 23 Vesicular transport protein SEC17 
6 1TJC A 8.1 1.9 13 Prolyl 4-hydroxylase alpha-1 subunit 
7 2K3W A 7.8 1.5 22 Vacuolar protein sorting-associating protein 
8 4AIF B 7.7 1.4 9 AH receptor-interacting protein  
9 4BT8 A 7.7 2 11 Prolyl 4-hydroxylase subunit alpha-1 
10 2IFU C 7.5 1.5 23 Gamma-SNAP 
 
The first two entries have been described in detail in the text. 
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Figure 4.9. Comparison of the structures of the top two DALI matches with the α II-α IV helical core 
of eEF-2K627-725 (green). The matched structures correspond to TPRs from the Pseudomonas 
translocator chaperone PcrH (blue, Z=9.7), and human Afadin (orange, Z=9.4). Part of the Afadin 
structure has been hidden for clarity in representation. In eEF-2K627-725, the αII-αIII fragment shows 
excellent structural alignment with the last TPR of PcrH, with αII aligning with helix A and αIII aligning with 
helix B of the helix(A)-loop-helix(B) motif. αIV corresponds to the C-terminal capping helix (Cap). For 
Afadin, the αII-αIII fragment aligns with an internal TPR and αIV matches helix A’ for the following TPR 
repeat, helix(A’)-loop-helix(B’). 
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Figure 4.10. Comparison of eEF-2K627−725 to TPR motif. (A) Comparison of sequence preferences 
(80% consensus) of the TPR motif predicted by SMART (top), the idealized TPR motif defined by Main et. 
al155 (middle) and the eEF-2K627-725 sequence (bottom). Conserved residue types are shaded purple; 
E671 on eEF-2K627-725 that deviates from the large hydrophobic group expected at this position is shaded 
red. The proline residue that is preferred at position 35 (shaded magenta) beyond the second helix, is 
missing in eEF-2K627-725.  For the PFAM preferences, h, t, u, a, p and s denote hydrophobic, turn-like, tiny, 
aromatic, polar and small, respectively. Also see Figure 4.8. (B) Comparison between the structures of 
the idealized TPR (left; the portion that aligns with αII and αIII on eEF-2K627-725 is shown in orange) and 
eEF-2K627-725 (right; only helices II and III are shown). Key residues (colored light purple) from the 
sequence comparison above are indicated. Similar residues are labeled in black; E671 (and the 
corresponding L10) that deviates from the expected consensus residue type is labeled in red; helix αIII for 
eEF-2K627-725 is longer by a turn than the idealized TPR; P35 (labeled in magenta) is missing in eEF-
2K627-725. 
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 As mentioned above, αI does not pack with the αII−αIV core; however, it contains a number of 
aromatic and hydrophobic residues. This would suggest that αI likely corresponds to the second (B) helix 
of the penultimate repeat, while the first (A) helix is not included within the boundaries of the eEF-2K627−725 
construct. The lack of tertiary structure would indicate that the missing interactions with the first helix (A) 
are required to stabilize the packing against the following repeat, and it is in fact likely that the boundaries 
of helix αI itself will be different in the context of a fully formed domain. The loop between αI and αII 
does not contain any defined secondary structure elements but does contain several hydro- phobic side 
chains, so it is possible that this region could adopt different structural features in the context of the full-
length protein. Functional Role of the Extreme C-Terminus of eEF-2K. Next, we investigated whether the 
structure of eEF-2K627−725 could be used to obtain insight into the mutational data of Pigott et al.48 It was 
shown that the deletion of the last 15 amino acids (711−725) is sufficient to abolish eEF-2 
phosphorylation, with minimal effects on the phosphorylation of the MH-1 peptide. On the basis of the 
structure of eEF- 2K627−725, deletion of the last 15 residues (Δ15) would result in the elimination of most of 
the C-terminal capping helix (αIV) and, with it, multiple stabilizing interactions with the remaining helices, 
most notably the interactions involving Y712, Y713, K715, A716, A719, and W720. Most importantly, 
Y712 and, to some extent, the smaller A719 take part in multiple interactions with both αII and αIII and 
stabilize the helical core (Figure 4.4). In contrast, deletion of the last eight residues (Δ8), and therefore 
only of the smaller A719 but not of Y712, would be expected to have a much more modest effect, as is 
seen.48 For the Q711−E718 segment, the removal of which completely abolishes eEF-2 phosphorylation, 
likely happens because the stabilizing interactions involving Y712 are eliminated. Pigott et al.48 also 
mutated several conserved residues in the 711−718 region of full-length eEF-2K to test for their effects on 
eEF-2 phosphorylation. Mutation of each of the two highly conserved tyrosine residues (Y712 and Y713) 
reduced the level of phosphorylation of eEF-2. In contrast, a Y712A/Y713A double mutation led to the 
complete loss of the ability of eEF-2K to phosphorylate eEF-2. As in the case of the deletion mutants (Δ
15 and the 711−718 segment), none of these single or double mutations had comparable effects on the 
ability to phosphorylate the MH-1 peptide. As described above, Y712 makes many hydrophobic contacts 
within the helical core of eEF-2K627−725; therefore, its alteration would be expected to destabilize the three-
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helix bundle to a greater extent than a Y713A mutation. Despite our best efforts, we failed to express the 
Y712A mutant and test its structural characteristics by NMR. However, we successfully expressed the 
Y713A mutant and found that the perturbations in the 15N−1H HSQC spectrum of this mutant when 
compared to that of wild-type eEF-2K627−725, were small and largely localized near the site of the mutation 
(Figure 4.11A). In contrast, the 15N−1H HSQC spectrum of the Y712A/Y713A double mutant reflected a 
characteristic cigar shape expected in unfolded proteins (Figure 4.11B). Interestingly, another C-terminal 
mutation, E717A, not only does not compromise eEF-2 phosphorylation but instead enhances the 
capability of eEF-2K to phosphorylate both eEF-2 and MH-1.48 In our NMR structure, E717 that is part of 
the C-terminal helix (αIV) is largely exposed to solvent, and the E717A mutation does not appear to 
affect the overall fold of this region (Figure 4.11C). As mentioned previously, the CTD of eEF-2K closely 
associates with the KD and modulates its activity. A bioinformatics analysis162 indicates that E717 
coevolves with R200 on the KD, a residue predicted to be exposed in our previously reported homology 
model of the KD.127 This could indicate that a possible E717−R200 salt bridge provides a point of contact 
between the CTD and the KD and that perhaps the E717A mutation alters the interface between the KD 
and CTD, thereby modulating kinase activity. Finally, we performed a set of preliminary experiments to 
test the suggested role of the CTD, specifically of its extreme C- terminus, in recognizing eEF-2. First, we 
tested the ability of a 19-residue peptide (R707−E725) that encompasses the segment of residues 
711−718 to inhibit eEF-2K-mediated phosphorylation of eEF-2. We found no difference in the rate of 
phosphorylation of eEF-2 in the absence or presence of 500 μM peptide (Figure 4.12A). Curiously, not 
only did the intact eEF-2K627−725 not provide any inhibition, its presence resulted in a slight increase 
(∼14%) in the rate of phosphorylation of eEF-2 (Figure 4.12B). Additionally, a low level of phosphorylation 
(data not shown) of eEF-2K627−725 itself was seen. This, as in the case of the E717A mutant, discussed 
above, could be the result of a reorganization of the KD−CTD interface, due to intermolecular binding of 
eEF-2K627−725 to the KD in competition with the intramolecular binding of the intact CTD (also underscored 
by eEF-2K627−725 phosphorylation). These results, taken together, suggest that neither the linear sequence 
encoded by the extreme C-terminus of eEF-2K nor the eEF-2K627−725 construct in isolation can efficiently 
engage eEF-2. 
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Figure 4.11. Comparison of 15N, 1H HSQC spectra of eEF-2K627-725 mutants.  15N, 1H HSQC spectra of 
various eEF-2K627-725 mutants – Y713 (A), Y712A/Y713A (B) and E717A (C). The spectrum of wild-type 
eEF-2K627-725 (blue) is shown in all cases for comparison. 
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Figure 4.12. eEF-2K627-725 cannot outcompete eEF-2K for eEF-2 binding. (A) Phosphorylation of 
wheat-germ eEF-2 (10 µM) by eEF-2K in the presence (squares) or absence (circles) of a 19-residue 
peptide (R707-E725) that encompasses the 711-718 segment of eEF-2K. (B) Phosphorylation of yeast 
eEF-2 (6 µM) by eEF-2K in the presence or absence of intact eEF-2K627-725 (20 µM). Top: Coomassie-
stained gel (upper panel) and autoradiography (lower panel) images of phosphorylated eEF-2 in the 
presence (-) or absence (+) of intact eEF-2K627-725. Molecular weight marker (M) is also shown. Bottom: 
quantification of eEF-2 phosphorylation by densitometry of the autoradiography image (left panel). The 
amount of phosphate incorporated into eEF-2 by eEF-2K (reported as pmol phosphate/pmol eEF-2) was 
quantified in the excised eEF-2 bands. 
  
 
 
3.5 – Conclusion 
Using NMR methodology, we have determined the solution structure of a 99-residue construct 
(eEF-2K627−725) that encodes the extreme C-terminus of eEF-2K. The structure of eEF-2K627−725 reveals 
that this region contains a three-helix core that is composed of a TPR-like motif capped by a C-terminal 
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helix. The N-terminal end of the construct also contains a helix that is largely unstable and does not pack 
against the C-terminal helical core. We expect that this helix is stabilized by additional interactions within 
the intact CTD that are absent in the construct studied here. It is likely to be part of another, not yet 
characterized, TPR-like motif. Further, the structure of this fragment provides a framework for interpreting 
the functional data of Pigott et al.48 that suggest that this region is required for the phosphorylation of 
eEF-2. The structural fold of the C- terminal helical core of eEF-2K627−725, as well as the NMR spectra of 
its Y712A/Y713A mutant, suggest that in the context of full-length eEF-2K this double mutation and the Δ
15 C-terminal truncation abolish eEF-2 phosphorylation by destabilizing the C-terminal capping helix and 
compromising the structural integrity of the CTD. Thus, the lack of activity toward eEF-2 appears to be the 
result of structural destabilization rather than a specific perturbation of a binding surface. Consistent with 
these observations, neither a peptide that includes the region of residues 711−718 of eEF-2K nor the 
eEF-2K627−725 construct in its entirety can interfere with the ability of full-length eEF-2K to phosphorylate 
eEF-2. Thus, our data indicate that the major determinants for the eEF-2 recognition are not uniquely 
contained within the last 15 residues of eEF-2K, as previously proposed.48 However, it is possible that the 
engagement of the other parts of the CTD, and perhaps also of the KD, is required for eEF-2K627−725 (and 
the segment of residues 711−718 therein) to attain the appropriate conformation to allow the binding of 
eEF-2. Clearly, additional work, both structural and biochemical, is necessary to fully resolve this issue. 
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Chapter 5 - Structural Dynamics of the Activation of Elongation Factor 2 Kinase by Ca2+-
Calmodulin 
The contents of this chapter were published as: 
Will et al. Structural Dynamics of the Activation of Elongation Factor 2 Kinase by Ca2+-Calmodulin. 
J. Mol Biol. in press (2018) 
© 2018 Elsevier Ltd. (reproduced with permission) 
5.1 Abstract 
Eukaryotic elongation factor 2 kinase (eEF-2K), the only known calmodulin (CaM) activated 
α−kinase, phosphorylates eukaryotic elongation factor 2 (eEF-2) on a specific threonine (Thr-56) 
diminishing its affinity for the ribosome and reducing the rate of nascent chain elongation during 
translation. Despite its critical cellular role, the precise mechanisms underlying the CaM-mediated 
activation of eEF-2K remain poorly defined. Here, employing a minimal eEF-2K construct (TR) that 
exhibits activity comparable to the wild-type enzyme and is fully activated by CaM in vitro and in cells, and 
using a variety of complimentary biophysical techniques in combination with computational modeling, we 
provide a structural mechanism by which CaM activates eEF-2K. Native mass analysis reveals that CaM, 
with two bound Ca2+ ions, forms a stoichiometric 1:1 complex with TR. Chemical crosslinking mass 
spectrometry (XLMS) and small angle X-ray scattering (SAXS) measurements localize CaM near the N-
lobe of the TR kinase domain and the spatially proximal C-terminal helical repeat. Hydrogen exchange 
mass spectrometry (HXMS) and methyl NMR indicate that the conformational changes induced on TR by 
the engagement of CaM are not localized, but are transmitted to remote regions that include the catalytic 
center and the functionally important phosphate binding pocket. The structural insights obtained from the 
present analyses, together with our previously published kinetics data, suggest that TR, and by inference, 
wild-type eEF-2K, upon engaging CaM undergoes a conformational transition resulting in a state that is 
primed to efficiently auto-phosphorylate on the primary activating T348 en route to full activation. 
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5.2 Introduction 
Elongation, the second of three broadly classified phases of translation23,163,164, is influenced by 
three major protein factors in eukaryotes: elongation factor-1α (eEF-1α), elongation factor-2 (eEF-2) and 
elongation factor-3 (eEF-3)16,165. While eEF-1α and eEF-3 are involved in recruiting aminoacyl-tRNAs to 
the ribosome, eEF-2 is responsible for the GTP-dependent translocation of the nascent chain from the 
ribosomal A-site to the P-site16,17,165. Addition of each new amino-acid residue to the elongating peptide 
chain requires the hydrolysis of GTP by eEF-2, to generate the energy for translocation166. 
Phosphorylation of eEF-2 on a specific threonine residue, Thr-5631–34,58,167, by eukaryotic elongation factor 
2 kinase (eEF-2K) significantly reduces its affinity for the ribosome and results in an overall reduction in 
rate of protein synthesis18,32,168. eEF-2K34,58 is a member of the α-kinase family169 that is largely unrelated 
in sequence to canonical protein kinases. eEF-2 is the only validated physiological substrate of eEF-2K, 
though other targets have recently been suggested170. 
The kinase activity of eEF-2K is upregulated by its interactions with calmodulin (CaM)31,167, 
making it the only known CaM-regulated α-kinase. However, this mode of activation contrasts that seen in 
other CaM-dependent kinases e.g. CaM kinase II (CAMKII) that involve displacement of a regulatory 
“pseudo-substrate” segment from its kinase docking region upon Ca2+-CaM binding exposing critical 
phosphorylation sites and the binding site for substrate171,172. This “release-of-inhibition” mechanism55,71 
appears not to be operative in eEF-2K, which utilizes a unique two-step allosteric activation mechanism37. 
Using comprehensive kinetic and biochemical techniques we have established that these steps are – 
(Step 1) the binding of Ca2+-CaM to eEF-2K resulting in a conformational change to generate a state that 
enables efficient auto-phosphorylation on a primary activating threonine, T34836,37 and (Step 2) the 
engagement of the phosphorylated T348 by a phosphate binding pocket (PBP) on the kinase domain 
leading to a further conformational change and resulting in a state with the highest activity towards the 
substrate eEF-2. However, in the absence of structural information for full-length eEF-2K and for the 
CaM•eEF-2K complex, the nature of the conformational transitions that facilitate these steps are not 
known. 
 Several biochemical and truncation studies37,49,51 have defined the domain organization of eEF-
2K (725 residues, 82.2 KDa), as shown schematically in Figure 5.1a. The N-terminus of eEF-2K 
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comprises of a non-canonical CaM-binding domain (CBD); we have recently determined the structure of 
this region bound to Ca2+-CaM(Figure 5.1b)53. The structure of the catalytic kinase domain (KD) that 
follows the CBD has been solved but the corresponding co-ordinates are not publicly available. The fact 
that the eEF-2K KD shares significant overall sequence identity with other α-kinases59,126 has allowed the 
construction of a robust homology model (Figure 5.1b)127. Bridging the KD and the C-terminal region 
(CTR; defined as the region between residues 490-725) that contains several α-helical repeats (HRs)60, is 
the regulatory loop (R-loop) that contains several positive and negative-regulatory phosphorylation sites12, 
in addition to the aforementioned T348. We have determined the structures of two different C-terminal 
constructs, CTR627-725 (this includes the final helical repeat, hence termed HR3)52 and CTR562-725 (that 
includes the last two helical repeats, hence termed HR23; Piserchio et. al, in preparation). The HR23 
construct (Figure 5.1b) represents approximately 70% of the CTR.  
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Figure 5.1. eEF-2K Kinase Truncation (a) Schematic representation of the full-length (FL) and truncated 
(TR) constructs of eEF-2K. TR is constructed by deleting 70 N-terminal residues and a section (359-489) 
of the regulatory loop (R-loop) of FL. The N-terminal calmodulin-binding domain (CBD) and the kinase 
domain (KD) are retained in TR, as are the C-terminal helical repeats (HR1, HR2 and HR3) along with the 
primary activating phosphorylation site (T348). The deleted segment of the R-loop (359-489) is replaced 
by a 6-glycine (G6) linker in TR. (b) The relevant modules for which validated structures are available are 
shown. The KD including residues H103-P330 is a homology model (blue), the HR23 construct of the 
CTR (G562-E725, purple) and the Ca2+-CaM•CBD complex (CaM in light blue, CBD, S74-A100, in 
orange) are NMR structures. The insets show the key residues (K205, R252 and T254) of the phosphate 
binding pocket (PBP) on the KD and the 1-5-8 binding mode (W85, I89 and A92) of the CBD on CaM 
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(that contains 2 Ca2+ ions at its N-lobe binding site; Ca2+ ions are absent from the C-lobe sites). The N- 
and C-termini of each module are indicated.  
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As eEF-2K plays a critical role in modulating a central physiological process, protein translation, it 
is tightly regulated through multiple signals. These include its primary activation by Ca2+-CaM and higher 
order regulation of activity by additional phosphorylation events mediated by kinases such as PKA173 and 
AMPK174, by pH6 and by cellular Ca2+ levels175. However, a necessary first step towards understanding 
this complex regulation of eEF-2K is to decipher in atomic detail the mechanism of its primary mode of 
activation that is mediated by Ca2+-CaM. Towards this goal, we developed a minimal construct of eEF-2K 
that lacks 70 residues at the N-terminus and a section (358-489) of the R-loop (Figure 5.1a), but contains 
both the primary activating auto-phosphorylation site (T348) and a second activating auto-
phosphorylation site, S500, that has been shown to play a key role under basal Ca2+ concentration175. 
Here, we show that this construct, that we term the TR construct of eEF-2K (TR in short; 530 residues 
including the 6-glycine linker, 60.2 KDa), is similarly activated by Ca2+-CaM as full-length eEF-2K in vitro 
and in cells. Further, we utilized a variety of mass spectrometric techniques including native mass 
spectrometry, hydrogen exchange mass spectrometry (HXMS), chemical crosslinking mass spectrometry 
(XLMS) together with solution NMR spectroscopy and small angle X-ray scattering (SAXS) to propose a 
structural mechanism by which Ca2+-CaM interacts with, and activates TR, and by inference, full-length 
eEF-2K. 
5.3 Results and Discussion 
5.3.1 TR forms a stable 1:1 complex with Ca2+-CaM   
All studies described below (with the obvious exception of the functional studies in vitro and in 
cells) have been performed using fully-dephosphorylated TR i.e. inactive TR. Therefore, in the present 
manuscript, all the biophysical studies described below, probe events involved in Step 1 (described 
above) to generate a conformation that enables efficient auto-phosphorylation on T348.  
Since TR contains the primary CaM-binding region53 (the CBD, Figure 5.1) of eEF-2K, we surmised that it 
would form a stoichiometric complex with Ca2+-CaM as in the case of full-length eEF-2K (FL). Indeed, TR 
forms a 1:1 complex with Ca2+-CaM as ascertained by size-exclusion chromatography (Figure 5.2) and 
native electrospray ionization mass spectrometry (see below). In order to investigate the nature of the 
Ca2+-CaM•TR complex more quantitatively, we injected the eluate (Figure 5.3) from a size-exclusion LC 
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column directly into an electrospray ionization mass spectrometer for native mass analysis (SEC/ESI-
MS)176. Ion peaks in the ESI-MS spectra of TR alone and in complex with Ca2+-CaM dominate the higher 
m/z region of the mass spectra (Figure 5.4). The lower charge-density ions, centered around the +16 
charge state for TR alone and the +17 charge state for the Ca2+-CaM•TR complex, represent compact, 
natively folded conformations. While both spectra also show the presence of higher charge-density ions 
(shown enclosed by the red rectangles in Figure 5.4) due to partially disordered structures with significant 
solvent accessibility87, the relative abundance of these peaks is higher in the mass spectrum of TR alone 
(top panel in Figure 5.4a) in comparison to the spectrum of the Ca2+-CaM•TR complex (bottom panel in 
Figure 5.4b). This is not surprising since the N-terminal CBD is likely to be disordered in the absence of 
Ca2+-CaM.  
 
 
 
Figure 5.2. Gel filtration traces of Free and CaM bound TR. Gel filtration traces of TR (black) and the 
Ca2+-CaM•TR complex (red; containing a slight excess of Ca2+-CaM) on a Hiload 16/60 Superdex 200 
(GE HealthCare Biosciences) column pre-equilibrated with buffer containing 20 mM Tris, 200 mM NaCl, 2 
mM DTT, 1 mM CaCl2 at pH 7.5.  Note that the isolated 71-358 and 490-725 constructs in the absence of 
the 6-glycine linker also form a stable complex. This linker was included in TR to reduce the number of 
exposed N- and C-termini that could potentially complicate the cross-linking studies described in the text. 
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Figure 5.3. In Line Gel filtration traces of Free and CaM bound TR for Native MS Analysis. TR (top 
panel) or the Ca2+-CaM•TR complex (containing a slight excess of Ca2+-CaM; bottom panel) was injected 
into a MAbPac SEC-1 size exclusion LC column pre-equilibrated with 50 mM ammonium acetate using a 
flow rate of 50 µL per minute. The eluate was continuously monitored by a UV detector and injected 
directly into a mass spectrometer for ESI-MS measurements.  The arrows (purple for TR alone, green for 
the Ca2+-CaM•TR complex and orange for Ca2+-CaM) indicate the start and end points of the elution time 
range for which the ESI-MS data were averaged to generate Figure 5.4. The dotted vertical lines indicate 
the elution times corresponding to maxima of the A280 for TR and the Ca2+-CaM•TR complex.     
  
In addition to peaks corresponding to the 1:1 Ca2+-CaM•TR complex, charge states that 
correspond to Ca2+-CaM transiently dissociated from the complex were also observed. A close inspection 
of these peaks reveals an isotopic distribution corresponding to CaM with 0, 1 and 2 bound Ca2+ ions but 
none with 3 or 4 Ca2+ ions (see inset of Figure 5.4b and Figure 5.5). This is in line with the presence of 
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only two Ca2+ ions seen in the structure of CaM in complex with a peptide corresponding to the CBD53. In 
contrast, free CaM, that was added in a slight excess to ensure the stability of the Ca2+-CaM•TR complex, 
and that appears at a higher elution volume on the size exclusion column (Figure 5.3) reveals peaks 
corresponding to 0, 1, 2, 3 and 4 bound Ca2+ ions, as expected (Figure 5.5). 
5.3.2 TR is active in vitro and in cells  
 Having confirmed the ability of TR to form a stoichiometric complex with CaM, we tested whether 
it retains the ability to be activated by Ca2+-CaM by measuring its efficiency in phosphorylating pep-S, an 
efficient peptide substrate of FL148. No phosphorylated product was seen in the absence of CaM in a 
Ca2+-containing buffer (Figure 5.6a). However, pep-S was efficiently phosphorylated by TR upon the 
inclusion of CaM with a kobs of 16.3±0.9 s-1 compared with a kobs of 14.5±0.3 s-1 for FL (Figure 5.6b), 
suggesting that the kinase activity of TR is stimulated by Ca2+-CaM to a similar extent as FL in vitro.  
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Figure 5.4. Native MS of eEF-2K TR and Ca2+-CaM•  eEF-2K TR complex. ESI-MS analysis of free TR 
(a) and the Ca2+-CaM•TR complex (b) averaged over specific fractions eluted from a gel filtration column 
(see Figure 5.3). Major charge states are labeled and states of higher charge corresponding to disordered 
regions (red rectangle) are also shown. For the Ca2+-CaM•TR complex shown in (b), charge states 
corresponding to a minor population of a 2:2, rather than a 1:1, complex are labeled in blue. Also shown, 
labeled in green, are the +7 and +8 charge states of free Ca2+-CaM dissociated from the Ca2+-CaM•TR 
complex. The inset shows an expansion of the +7 charge state with the isotopic distributions resulting 
from 0, 1 and 2 bound Ca2+ ions. Also see Figure 5.5.  
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Figure 5.5. Calcum Saturated CaM is Observable with Native MS.The top panel shows an expansion 
of m/z range corresponding to the +7 charge state of the CaM peak transiently dissociated from the Ca2+-
CaM•TR complex during ESI-MS (derived from the fractions between the green arrows in Figure 5.3; the 
expanded spectrum is shown in Figure 5.4). The bottom panel shows a corresponding region for the free 
CaM in solution (the region between the orange arrows in Figure 5.3) i.e. CaM that did not dissociate from 
the Ca2+-CaM•TR complex during ESI-MS. The isotopic distributions in the spectra suggest that Ca2+-
CaM in the Ca2+-CaM•TR complex contains 2 Ca2+ ions leading to peaks corresponding to 0, 1 and 2 ions 
(top panel). This contrasts free Ca2+-CaM that can bind upto 4 Ca2+ ions (peaks corresponding to 0, 1, 2, 
3 and 4 ions are seen on the bottom panel). 
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To evaluate the behavior of TR in cells, vectors encoding either vector alone (CV), TR or FL were 
transfected into MCF-10A (eEF-2K-/-) cells37 that lack endogenous eEF-2K. While the cellular levels of TR 
were found to be ~3-fold lower than that of FL (Figure 5.6C), the relative levels of eEF-2 phosphorylated 
on Thr-56 were found to be comparable in the TR and FL transfected cells (Figure 5.6c, left panel). This 
suggests that the activity of TR is significantly higher than that of FL in cells (Figure 5.6c, right panel). 
This is not surprising since the negative regulatory phosphorylation sites on the R-loop e.g. S359 and 
S366 (along with the positive regulatory site, S398) are missing in TR12. Nevertheless, taken together with 
the in vitro data, our results suggest that TR retains its ability to be upregulated by Ca2+-CaM and to site-
specifically phosphorylate eEF-2 on Thr-56. 
5.3.3 Ca2+-CaM binding leads to greater solvent protection in specific regions of TR 
 We used hydrogen deuterium exchange mass spectrometry (HXMS) to estimate the extent of 
solvent exposure of backbone amide positions in TR by measuring the degree of 2H incorporation upon 
incubation with D2O for varying lengths of time (5, 10, 30 and 240 minutes). About 35% of the amide 
protons of TR were replaced by 2H within the first 5 minutes of incubation. This was followed by slower 
incorporation of an additional ~11% over four hours, suggesting that more than half the amide positions in 
TR were well shielded from solvent (Figure 5.7). Absent a correction for back exchange, this number 
represents a lower bound of the TR protons that are solvent-exchangeable over this timeframe. While 
HXMS data for the Ca2+-CaM•TR complex (MS analysis following 5, 10, 30, 60 and 240 minutes of 
incubation in D2O) revealed similar overall trends as for TR alone, the presence of Ca2+-CaM resulted in 
increased overall protection (Figure 5.7). This decreased solvent accessibility can be attributed to 
increased steric shielding (due to Ca2+-CaM binding), decreased dynamics, or both.  
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Figure 5.6. eEF-2K TR has the same activity as eEF-2K. (a) The activity (picomoles of product per 
picomole of enzyme) of TR as ascertained through its ability to phosphorylate an optimal peptide 
substrate (Pep-S) is stimulated by calmodulin (CaM) in the presence of Ca2+ (red). TR cannot 
phosphorylate Pep-S in the absence of CaM (green). (b) TR (blue) and FL (red) show similar activity 
towards Pep-S in the presence of Ca2+-CaM. The inset shows the kobs values, determined using the initial 
rate regime, for the two cases. Each datum represents an average of duplicate measurements. (c) 
Western blot analyses show lower levels of TR compared to FL in MCF-10A (eEF-2K-/-) cells following 
transient transfection, but comparable levels of eEF-2 phosphorylated on Thr-56 (all measurements in 
duplicate). eEF-2 levels in cells transfected with vector alone (CV), or in those expressing TR or FL, are 
shown. Pan-actin is used as loading control. The right panel shows the relative activities of TR and FL (as 
measured through Thr-56 phosphorylated eEF-2 levels; averaged over duplicate measurements) 
normalized to the cellular levels of each construct. 
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 In order to determine the specific regions of TR that show increased protection in the presence of 
Ca2+-CaM, we relied on local HXMS measurements. TR in the apo state, or that in the context of the 
Ca2+-CaM•TR complex, was digested using an immobilized pepsin column after incubation in D2O for 
varying lengths of time (5, 10, 30 and 60 minutes). The peptides generated were subjected to low 
temperature HPLC-ESI-MS/MS analysis. In all, data for 196 overlapping peptides (representing 90.4% 
coverage of the TR sequence; see Figure 5.8 for a representative dataset) could be analyzed. Of these, a 
total of 40 peptides displayed statistically significant increase in protection induced by Ca2+-CaM. None of 
the peptides for which data could be analyzed showed a statistically significant decrease in protection in 
the presence of Ca2+-CaM. The largest overall increase in protection was seen in the β-barrel on the N-
lobe of the KD including β2, β3, β4 and β5 (Figure 5.9). Increased protection was also seen on the 
phosphate-binding P-loop and at the C-terminal end of αC, that along with the αD (that also shows 
somewhat increased protection; see peptide 7 in Figure 5.9), constitutes the PBP, a pocket proposed to 
accommodate phosphorylated T348, following its auto- phosphorylation.  Occupancy of the PBP by 
phosphorylated T348 drives the second conformational transition (as part of Step 2, described above) 
that facilitates the formation of the fully-active form of eEF-2K37. Peptides corresponding to the αE helix 
(peptide 8 in Figure 5.9) and the β5-αC loop (that connects the N-lobe β-barrel to αC; peptide 5) also 
showed increased protection in the presence of Ca2+-CaM.  
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Figure 5.7. Intact Mass HXMS of Ca2+-CaM•TR and Free TR. Representative bulk 2H uptake HXMS 
curves for TR alone (black) and the Ca2+-CaM•TR complex (red). The circles represent the experimental 
data (5, 10, 30 and 240 minutes of D2O incubation for TR alone and 5, 10, 30, 60 and 240 minutes for the 
Ca2+-CaM•TR complex) and the solid lines represent multi-exponential fits through the experimental data 
for visual guidance. 
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Figure 5.8. Local HXMS of Ca2+-CaM•TR and Free TR. Representative dataset illustrating the difference 
in 2H uptake in TR in the presence or absence of Ca2+-CaM. Each block represents a peptide and the four 
rows for each peptide represent differences for the 5, 10, 30 and 60-minute datasets. Δ for a given 
peptide is defined as follows: 
Δ (%) = 100 𝐻!!"#!"#  −  𝐻!!"#!"#!! 𝐻!"#!"#!  
Where 𝐻!!"#!"#!  and 𝐻!!"#!"#!  represent 2H incorporation in the presence and absence of CaM for a given 
peptide, respectively. 𝐻!"#!"#!  represents the maximum possible 2H incorporation for that particular 
peptide. Δ > 0 (deeper shades of red) indicates greater protection in the presence of Ca2+-CaM. Important 
loops, residues that correspond to the phosphate binding pocket (PBP) and key phosphorylation sites 
(T348 and S500), are indicated. The glycines corresponding to the G6 linker that connects G358 to N490 
are shown in larger font. The black arrows indicate peptides for which the 2H incorporation curves are 
shown in Figures 4 and 5. 
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Figure 5.9. CaM binding Increases protection of Kinase Domain from Hydrogen/Deuterium 
Exchange. (a) Results of a representative HXMS dataset using a 60-minute D2O-incubation period 
mapped onto the homology model of the KD of eEF-2K. Specific regions of the KD discussed in the text 
are indicated. Each residue has been colored according to a Δav value (using a cyan to magenta gradient; 
residues with no peptide coverage have been colored black) defined as:  
Δ!" (%) = 100 𝐻!!"#!"#  −  𝐻!!"#!"#!! 𝐻!"#!"#! !"!#$%"& 
Where 𝐻!!"#!"#!  and 𝐻!!"#!"#!  represent 2H incorporation in the presence or the absence of CaM for a given 
peptide and 𝐻!"#!"#!  represents the maximum possible 2H incorporation for that peptide. The <> denotes 
an average over all peptides that contain a given residue e.g. in Figure 5.8, N77 is contained in 2 
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peptides, W85 in 1 peptide, L104 in 7 peptides. Note that Δ > 0 indicates increased protection i.e. reduced 
2H incorporation in the presence of CaM. (b) Time-course of 2H incorporation for selected peptides that 
show statistically significant differences in the absence (black) and the presence (red) of Ca2+-CaM. The 
data represent average and standard deviation values determined from three separate measurements. 
The location of the peptides on the homology model of the KD are indicated using specific colors (the 
corresponding colors are used in numbering the peptides on the 2H incorporation curves). Also shown on 
the lowest panel (labeled as Ref) for comparison is a peptide for which no statistically significant change 
in protection was seen. The bound ADP and sidechains of K132, E145 and K162 that have been shown 
to cross-link with CaM are shown in stick representation and labeled. 
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 We have previously shown that the N-terminal CBD comprises the primary CaM binding region of 
eEF-2K (and by inference, of TR)53. However, a single peptide (77-86) that includes only one (W85) of the 
critical CaM binding residues (CBD engages CaM in a 1-5-8 binding mode: W85-I89-A92; Figure 5.1b), 
albeit the most important one, could be resolved in our local HXMS measurements (see Figure 5.8). 
While this peptide showed an overall trend suggesting increased protection in the presence of Ca2+-CaM, 
the differences between the free and bound states were within the error bounds (not shown).  
Some parts of the CTR also showed statistically significant changes in protection upon Ca2+-CaM 
binding. Increased protection was seen on three contiguous helices (α3’, α4’ and α5’; Figure 5.10) 
belonging to the second (HR2) and third (HR3) helical repeats. Other regions of TR did not show any 
statistically significant changes in protection in the presence of Ca2+-CaM.  
5.3.4 Specific cross-links indicate the relative spatial location Ca2+-CaM and the structural 
domains of TR 
 While the spatial organization of the structural domains of intact TR is unknown in the absence of 
a three-dimensional structure, it is difficult to conceive that all of the regions that show increased 
protection in the HXMS studies, discussed above, could simultaneously interact with CaM in the context 
of a heterodimeric complex. For example, it seems unlikely that the N-lobe of the KD and the PBP could 
both directly interact with CaM without large-scale distortions in the structures of TR, CaM, or both.  Thus, 
in order to parse the effects of direct interactions with CaM on the HXMS-determined solvent protection 
from those that result from structural rearrangements within TR as a consequence of CaM-binding i.e. 
long-range allosteric effects, we relied on the chemical cross-linking mass spectrometry (XLMS) 
measurements98,106.  
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Figure 5.10 CaM binding Increases protection of eEF-2K562-725 from Hydrogen/Deuterium 
Exchange. (a) Δav values from a selected 60-minute dataset mapped onto a representative structure from 
the NMR ensemble of HR23 construct using the same approach as in Figure 5.9. Only the region (G597-
E725) that is ordered in the NMR structure is shown. The coloring scheme is the same as in Figure 5.9A. 
(b) 2H-incorporation time courses for peptides from the CTR that show statistically significant differences 
in the presence (red) and absence (black) of Ca2+-CaM. The location of the peptides on the HR23 
structure are indicated using specific colors (the corresponding colors are used in numbering the peptides 
on the 2H incorporation curves). The sidechain of K715 that cross-links with CaM is shown in stick 
representation. 
 We utilized the “zero-length” carbodiimide cross-linker EDC that links primary amines (N-terminus 
and lysine sidechains) to glutamate, aspartate sidechains and the C-terminus177. The cross-linked species 
were digested with trypsin and the resulting peptides were analyzed using ESI-MS/MS. Several cross-
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linked peptides could be identified but only 7 could be localized to within segments on the interacting 
partners (the KD and CTR of TR and CaM) that were short enough to be useful as constraints (see 
Figures 3.15 and 3.16 for specific fragmentation patterns). 
As shown in Table 5.1, a total of four inter-protein (Inter) cross-links between TR and CaM could 
be identified, in addition to three inter-domain cross-links within TR (IntraTR) (Figure 5.11 and 4.*16). Of 
the cross-links between CaM and TR, both ends of the cross-link (using a one-letter code for TR residues 
and a three-letter code for CaM residues) could be uniquely identified for two - E145-Lys30 (Inter-2 in 
Table 5.1) and K715-Glu87 (Inter-4 in Table 5.1). In addition, K132 and K162 on TR were identified as 
forming cross-links with acidic residues on CaM (Inter-1 and Inter-3 in Table 5.1).  It is notable that E145, 
K132 and K162 are all localized on the N-lobe of the TR KD in regions that display increased protection in 
the presence of Ca2+-CaM (Figure 5.9) in the HXMS measurements. 
 
 
 
Figure 5.11. Fragmentation pattern for the cross-links between CaM and TR listed in Table 5.1. U or 
A imply unambiguous or ambiguous identification of cross-linked partners, respectively. For example, U/U 
(Inter-4) signifies a situation where both cross-linked residues have been unambiguously identified. The 
corresponding sequences are shown at the bottom of each panel and the cross-linked residues are 
shown in red (peptide 1) and blue (peptide 2). 
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Figure 5.12. The fragmentation patterns for inter-domain inter-domain (between the KD, CBD and 
TR) cross-links within TR listed in Table 5.1. Labeling and coloring schemes are as in Figure 5.11. 
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Table 5.1. List of cross-links between TR and CaM and between the domains of TR 
  
Number  Peptide 1 Region Peptide 2 Region Crosslinked Residues 
Cross-Links between TR and CaM  
Inter-1 117YNAVTG
EWLDDEVL
IKMASQPF
GR140 
KD 38SLGQNPTEA
ELQDMINEVD
ADGNGTIDFPE
FLTMMAR74 
CaM (N-lobe) K132:Glu45/Glu47/Asp50 
Inter-2 141GAMREC
FR148 
KD 22DGDGTITTKE
LGTVMRSLGQ
NPTEAELQDMI
NEVDADGNGT
IDFPEFLTMMA
R74 
CaM (N-lobe) E145:Lys30 
Inter-3 151KLSNFLH
AQQWK162 
KD 38SLGQNPTEA
ELQDMINEVD
ADGNGTIDFPE
FLTMMARK75 
CaM (N-lobe) K162:Glu45/Glu47/Asp50 
Inter-4 708LANQYY
QKAEEAW
AQMEE725 
CTR 87EAFR90 CaM (C-lobe) K715:Glu87 
Cross-links between the domains of TR 
IntraTR-1 87HAIQKAK9
3 
CBD 685DPQR688 CTR K93:D685 
IntraTR-2 509LNALDLE
KK517 
CTR 248DDNIR252 KD K516/K517:D248 
IntraTR-3 517KIGK520 CTR 248DDNIRLTPQ
AFSHFTFER265 
KD K517/K520:D248/D249 
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Given that the CBD, which is critical for the recognition of Ca2+-CaM, is located immediately N-
terminal to the N-lobe of the KD, it stands to reason that CaM bound at the CBD is likely to be in physical 
proximity to the N-lobe of the KD and indeed poised to interact with it in the Ca2+-CaM•TR complex. Thus, 
this increased protection seen for the N-lobe of the KD, in the HXMS studies described above, most likely 
results from a direct interaction with Ca2+-CaM. Indeed, our previous studies have indicated a somewhat 
reduced affinity of a peptide encoding only the CBD (KD ~245 nM) towards Ca2+-CaM compared to that of 
full-length wild-type eEF-2K (KD ~17 nM)53, suggesting that additional stabilizing contacts could exist 
between Ca2+-CaM and eEF-2K. On the other hand, it is difficult to conceive of a scenario where Ca2+-
CaM engaged by the CBD and docked at the N-lobe of the KD could simultaneously interact with the 
PBP. Therefore, the increased protection seen at the PBP in the presence of Ca2+-CaM likely results from 
a conformational change that is transmitted from the CaM docking site at the N-lobe of the KD as 
explored in greater detail below. 
The inter-domain cross-links within TR provide a means to assess the spatial locations of the 
various domains of TR with respect to each other; the most useful amongst these is the unambiguous 
K93-D685 crosslink (IntraTR-1 in Table 5.1) that places the C-terminal region of TR (specifically HR3) 
close to the N-lobe of the KD. It is notable that K93 lies immediately C-terminal to residue 8 (A92; see 
Figure 5.1b) of the CBD segment that engages CaM in a 1-5-8 binding mode. This would suggest that the 
HR3 is also proximal to CaM, an arrangement that is supported by the observed cross-link between K715 
and Glu87 (Inter-4 in Table 5.1). It is notable, however, that this region shows only a small increase in 
protection upon Ca2+-CaM binding in the HXMS measurements suggesting that while in spatial proximity 
to CaM, it does not participate in a direct interaction with it, unlike the N-lobe of the KD.  
Next, we tested the utility of the cross-links listed in Table 5.1 as inputs for the generation of a model of 
the Ca2+-CaM•TR complex using the homology model of eEF-2K KD127 together with the NMR structures 
of HR23 construct (Piserchio et al., in preparation) and the Ca2+-CaM•CBD complex53. First, we needed to 
assess whether the individual structures of the KD, HR23 and Ca2+-CaM•CBD complex (Figure 5.1b) 
were maintained in the context of the Ca2+-CaM•TR complex. We used a set of cross-links within the KD 
and CTR modules of TR and within CaM itself to validate the structures. As evident from Table 5.2, the 
distances between residues found to be cross-linked in the context of the Ca2+-CaM•TR complex were 
 86 
within reasonable distances of each other (generally < 23 Å)178 in the structure of isolated HR23, and to a 
large extent, for the homology model of the KD. This suggests that the structures of these modules are 
largely maintained in the context of the Ca2+-CaM•TR complex. The situation was drastically different for 
CaM, with the distances between cross-linked pairs calculated using the structure of the Ca2+-CaM•CBD 
complex were found to be too large to allow efficient cross-linking if the structure were to be maintained. 
This scenario is best embodied by the observed cross-link between Lys30 on the N-lobe of CaM with 
Glu127 on its C-lobe. These residues have a Cα-Cα distance of ~37 Å in the context of the Ca2+-
CaM•CBD complex, placing them at a distance that would not enable cross-linking. In contrast, the intra-
C-lobe distances between the cross-linked residues Lys94 and Glu127/Asp129 (Table 4) are far more 
reasonable at ~17-20 Å. These data suggest that the inter-lobe orientation in the Ca2+-CaM•TR complex 
is quite different from that represented in the Ca2+-CaM•CBD NMR ensemble. Given this scenario, it is not 
surprising that while our efforts to model the KD•CTR496-725 complex (see Materials and Methods section 
for details) yielded converged structures (Figure 5.13), our attempts to include Ca2+-CaM•CBD in this 
model did not lead to convergence.  
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Table 5.2. List of cross-links within the domains of TR and within CaM 
Residue 1  Residue 2  Cα-Cα  Distance (Å) 
TR 
K150 (KD) E174/D177 (KD) 24.0/24.6 
K170 (KD) D177 (KD) 13.7 
K594 (CTR) D629 (CTR) 11.5a 
K684 (CTR) E717/E718/E725 (CTR) 16.1/14.2/14.0a 
CaM 
Lys30 (N-lobe) Glu127 (C-lobe) 36.6b 
Lys77 (C-lobe) Glu31 (N-lobe) 26.1b 
Lys94 (C-lobe) Glu127/Asp129 (C-lobe) 20.1/17.7b 
 
aAverage distance based on the NMR structural ensemble of eEF-2K562-725 (PDB: to be submitted) 
bAverage distance based on the NMR structural ensemble of the Ca2+-CaM• eEF-2KCBD complex (PDB: 
5J8H) 
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As shown in Figure 5.14, the structural model for the KD•CTR496-725 complex is consistent with all 
the observed inter-domain crosslinks within TR. Indeed, the model is also consistent with the crosslinks 
with segments of TR that were not explicitly included in the model itself e.g. it is completely plausible for 
D685, that is spatially proximal to the N-terminus, to cross-link with K93, a part of the N-terminal CBD 
(Figure 5.1b), that is not represented in the model. This suggests that the computational model 
represents a plausible organization of the domains of TR in the context of the Ca2+-CaM•TR complex. 
While this analysis does not provide a structural model for CaM within the complex, the locations of K132, 
E145, K162 and K715, all of which cross-link with CaM (Figure 5.14b), suggest a spatial localization of 
CaM near the N-lobe of the KD and the C-terminus of the CTR near HR3.  
5.3.5 Ca2+-CaM binding leads to allosteric effects in the TR kinase domain 
 For the computational model described above, there are regions of TR that show increased 
protection from solvent in the presence of Ca2+-CaM in the HXMS studies but are not found to be spatially 
proximal to it (Figure 5.14c). These regions include the PBP and parts of the CTR in which increased 
protection from solvent likely results from conformational changes that result upon the engagement of the 
CBD and the N-lobe of the KD by Ca2+-CaM. For an additional orthogonal test of this hypothesis, we 
utilized methyl TROSY NMR spectroscopy using the δ1 positions of the 20 Ile residues of TR179. The Ile 
δ1 resonances were assigned by comparison of 13C,1H SOFAST-HMQC180  spectra of wild-type 13C,1H-
Ile-δ1-labeled TR with corresponding spectra of point mutants where a particular Ile was replaced by Leu 
(except I232A and I522S). Using this approach 15/20 Ile-δ1 resonances were unambiguously assigned 
(Figure 5.16). Resonances corresponding to I89 and I349 could not be uniquely identified but were 
attributed to a single cluster along with I237. I131 and I215 are proximal in space on the N-lobe of the KD 
and mutation of one altered the resonance position of the other, though this exercise allowed narrowing 
down the corresponding assignments to a pair of well-resolved resonances.  
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Figure 5.13. Plot of the interface score of the final structures of the KD•CTR496-725 complex. Plot of 
the interface score in Rosetta Energy Units (REU) of the final cluster of 264 structures of the KD•CTR496-
725 complex against the interface root mean squared deviation (RMSD) from the best scoring decoy 
(shown in Figure 5.14). Structures with acceptable interface energies (-5 REU or lower) center around 
three distinct interfaces that are within ~4, ~14, or ~17 Å from the reference decoy.  The lowest point in 
each cluster represents a local minimum in the energy landscape, decoys that center around it also score 
consistently within the acceptable range. The cluster with RMSD values ranging from 0 to 4 Å contains 
the decoys with the best interaction energies and represents the deepest well in the interaction energy 
landscape. Decoys from this cluster were accepted to be representative of the global minimum.    
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Figure 5.14. Structural Model of the eEF-2K Kinase Domain in Complex with eEF-2K490-725. (a) 
Computational model of the KD•CTR496-725 complex using a homology model of the KD (shown in blue), 
the NMR structure of CTR597-725 (extracted from HR23, shown in purple); the structure of the remaining 
fragment has been modelled using Rosetta (shown in grey). The N- and C-termini of each fragment are 
labeled. (b) Sidechains of the residues that form cross-links between the KD and the CTR (IntraTR-2 and 
IntraTR-3 in Table 5.1) are shown in stick representation. Sidechains of cross-linked residues are shown 
red (peptide 1) and cyan (peptide 2), respectively. These cross-links were used as constraints in 
generating the model for the KD•CTR496-725 complex. Note that D685 (shown in blue) cross-links (IntraTR-
1 in Table 5.1) with the N-terminal K93 (that belongs to the CBD, in orange) that is not part of the model. 
Sidechains of residues that cross-link with CaM listed in Table 5.1 are shown and labeled in magenta. (c) 
Locations of the peptides that show statistically significant differences in protection in the HXMS 
measurements in the presence of Ca2+-CaM are colored red (peptides 1-8 from Figure 5.9 and peptides 
1-3 in Figure 5.10). 
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 As expected, several Ile resonances showed significant perturbations in the presence of Ca2+-
CaM (Figure 5.15a). These include I131 and I215, located on the N-lobe of the KD, as well as I251, I271, 
and I275 all of which lie at or near the PBP. Resonances corresponding to residues I209, I232 and I287, 
that lie near the catalytic site, are not identifiable in the bound form (most likely due to extremely large 
chemical shift changes), suggesting substantial conformational rearrangements at the catalytic center. An 
inspection of Figure 5.15b reveals that the perturbed Ile residues form a connected network extending 
from the N-lobe of the KD to the PBP. This indicates a likely pathway by which conformational changes 
induced by the engagement of the N-lobe of the KD by Ca2+-CaM could be transmitted to remote sites 
including the PBP. The likely existence of this long-distance communication network is underscored by 
the fact that a T348A mutation leads to a ~10-fold decrease in the affinity of eEF-2K for CaM37. In contrast 
to the KD, most of the Ile residues on the CTR are not located in regions that show significant protection 
in the presence of Ca2+-CaM (Figure 5.16) in the HXMS measurements. The resonance corresponding to 
I614, that lies in this region, does show some broadening but this perturbation is not as significant as that 
seen for the KD resonances. 
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Figure 5.15. CaM Binding Induces Chemical Shifts of Ile methyl groups across both lobes of the 
eEF-2K Kinase Domain. (a) 13C,1H HMQC spectra (800 MHz) of 13C,1H-Ile-δ1, 2H-labeled TR in the 
absence (green) or presence (magenta) of CaM in a Ca2+-containing buffer. The resonances that show 
significant perturbations are labeled in blue. The resonances corresponding to the spatially contiguous 
I131 and I215 (enclosed by the black rectangle) that could not be uniquely assigned yet are both 
perturbed (one disappears and the other shows a significant change in resonance position) are labeled 
using light blue lettering. (b) The spatial distribution of the perturbed residues is indicated on the 
homology model of the KD using spheres, colored and labeled using the same scheme as in (a). 
 
 
Figure 5.16. Assigned 13C,1H-Ile-δ1 HMQC and the Distribution of Ile Residues on the Model of the 
KD•CTR496-725 Complex. The left panel illustrates a 13C,1H HMQC spectra (800 MHz) of 13C,1H-Ile-δ1, 2H-
labeled TR in a Ca2+-containing buffer with the resonances labeled with their corresponding assignments. 
The resonances corresponding to the spatially contiguous I131 and I215 (enclosed by the green 
rectangle and labeled in green) could not be uniquely assigned. I89, I349 and I237 belong to a single 
unresolved cluster as do I522 and I614. The right panel shows the distribution of Ile residues on the 
model of the KD•CTR496-725 complex. The colors of the labels are the same as in the left panel. I89 (CBD) 
and I349 (R-loop) that are labeled in orange and grey, respectively, are not present in the model. I317 
(labeled in cyan) that lies in the Zn2+-. Locations of the peptides that show statistically significant 
differences in protection in the HXMS measurements in the presence of Ca2+-CaM are colored red as in 
Figure 5.14c.  
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5.3.6 SAXS measurements suggest an elongated structure for the Ca2+-CaM•TR complex 
We used small angle X-ray scattering to determine the overall hydrodynamic features of the Ca2+-
CaM•TR complex. The complex showed no signs of aggregation over more than a 3-fold range of 
concentration (from 1.9 mg/mL to 6.4 mg/mL; Figure 5.17a). This contrasts the behavior of TR alone that 
showed significant aggregation at moderate-to-high concentration (Figure 5.18). An analysis of the SAXS 
data using GNOM181 within the ATSAS suite182 produced a radius of gyration (RG, see Table 5.3 for 
details) of ~37 Å and Dmax of ~130 Å (Figure 5.17b). The expected RG value for a globular species of the 
same number of amino-acid residues as the Ca2+-CaM•TR complex is expected to be roughly 26 Å183, 
suggesting that the complex forms an elongated structure in solution. This is also borne out by the 
molecular envelope calculated from the SAXS data that suggests a species that is approximately 130 Å 
by 92 Å by 34 Å in solution (Figure 5.17c). Using the modeled structure of the KD•CTR496-725 complex 
(described above) in addition to that of Ca2+-CaM•CBD tethered to the N-terminus of the KD using a 
flexible linker, we used CORAL182 in combination with the 6.4 mg/mL SAXS data to model a structure of 
the Ca2+-CaM•TR complex without the use of any additional constraints. As shown in Figure 5.17c, the 
model shows CaM localized near the N-lobe of the KD and the C-terminal end of CTR. In addition, the 
various structural modules are accommodated well into the SAXS-determined molecular envelope. It is 
interesting to note that even when we did not tether the Ca2+-CaM•CBD module to the N-terminal region 
of the KD using a flexible linker during the CORAL182 calculations, there was little variation in the N-
terminal localization of the former, in agreement with the cross-linking data discussed above. Thus, TR 
forms a hatchet-shaped complex with Ca2+-CaM, the former comprising the blade and the latter, the 
handle, as shown in Figure 5.17c. 
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Figure 5.17. SAXS Analysis of CaM Bound eEF2K TR. (a) Plot of the SAXS data of the Ca2+-CaM•TR 
complex at two different concentrations, 1.9 mg/mL (red) and 6.4 mg/mL (blue). The data have not been 
normalized with respect to concentration. The corresponding Guinier regions are shown in the inset. (b) 
Concentration normalized pair distribution functions for the SAXS data from (a). (c) The hatchet shaped 
molecular envelope generated from the SAXS data for the 6.4 mg/mL sample showing the approximate 
dimensions based on the diameters along the three principal axes of the inertia tensor calculated using 
UCSF Chimera. The spatial locations of CaM (light blue), CBD (orange), KD (dark blue) and CTR496-725 
(purple) in the context of the KD•CTR496-725 complex determined using CORAL (χ2=1.52) are shown. 
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Figure 5.18. Concentration-scaled SAXS curves for apo TR at three different concentrations. The 
deviation between the three curves at low q values (indicated by the green dashed oval) suggests 
concentration dependent aggregation. The I0/c values were 1.30±0.02, 1.69±0.02, 2.16±0.03 for 
concentrations of 3 mg/mL, 5 mg/mL and 10 mg/mL, respectively. The corresponding RG values were 
45.7±1.2 Å, 55.0±1.2 Å, 64.9±1.2 Å. 
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Table 5.3. Results of SAXS analysis on the Ca2+-CaM•TR complex 
  
Concentration (mg/mL) 1.9 6.4 
Guinier Analysis 
I0/c 1.34±0.01 
1.26±0.00 
RG (Å) 35.5±0.4 
34.7±0.4 
qmin 0.01234 0.01665 
qmaxRG 1.25 1.27 
Molecular Mass Analysis (Da) 
MW from QP (qmax)  76955 (0.1971) 74302 (0.2185) 
MW from Vc (Vc; qmax) 68580 (548; 0.3011) 66871 (534;0.3011) 
Bayesian credibility interval (MW) 
67900-75300 (72400) 
69650-75300 (72400) 
P(r) Analysis 
RG (Å) 
37.45±1.36 
36.53±1.29 
Dmax (Å) 130 128 
q range 0.0195-0.2250 0.0238-0.2293 
χ2 0.8294 0.8360 
DAMMIF (20 runs, default parameters) 
q range 
0.0195-0.2250 
0.0238-0.2293 
Symmetry/anisometry P1/unknown 
P1/unknown 
NSD 1.384±0.183 
1.166±0.113 
χ2 range 
0.765-0.767 0.971-0.977 
Resolution from SASRES (Å) 42±3 
37±3 
MM (0.5×volume) (Da) 69140±390 
66870±315 
DAMMIN 
q range 
0.0195-0.2250 
0.0238-0.2293 
χ2 
0.7928 0.9723 
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5.4 Conclusions 
 We have developed a minimal construct of eEF-2K lacking a significant segment of its N-terminus 
and most of the regulatory R-loop linking the kinase domain to the C-terminal region. The presence of the 
N-terminal CaM-binding domain and the section of the regulatory loop including T348, the site of primary 
activating auto-phosphorylation, ensures that this minimal construct (TR) is activated by Ca2+-CaM to a 
similar extent as full-length enzyme in vitro while retaining its ability to efficiently phosphorylate eEF-2 on 
Thr-56 in cells.  Analysis of chemical crosslinking data using mass spectrometry and computational 
modeling suggest a topology for TR in which the C-terminus of the CTR (HR3) is spatially proximal to the 
N-lobe of the KD, and where both of these regions lie in close proximity to CaM in the Ca2+-CaM•TR 
complex. Increased protection against 2H exchange with solvent in HXMS studies suggests that CaM, 
that is anchored to its primary binding site at the N-terminal CBD, is likely stabilized further by additional 
interactions with the N-lobe of the KD. The importance of these latter interactions is also borne out by the 
fact that the affinity of Ca2+-CaM towards a peptide encoding the CBD is ~15-fold lower than that 
compared to full-length eEF-2K. It is also notable that an affinity of ~1 µM remains even upon mutation of 
the key CaM-anchor residue on the CBD (W85S)53. A preponderance of validated cross-links between the 
N-lobe of CaM (3 of 4 cross-links with TR involve the N-lobe of CaM; see Table 5.1) and the TR KD 
seems to suggest that the N-lobe of CaM is more proximal to TR than the CaM C-lobe. Though additional 
data are needed to confirm this hypothesis.  
It is noteworthy that regulatory interactions involving the N-lobe of the kinase domain are not 
unprecedented in α-kinases. The KD of the Ca2+-dependent TRP channel is active as a head-to-head 
domain swapped dimer that forms through the interactions of an N-terminal helical segment of one 
protomer that packs against the αC helix of the second (Figure 5.19)126. This interaction involves 
significant contacts between the N-lobe β-barrel regions of the two protomers. Truncation/deletion of this 
N-terminal segment or mutation of specific residues therein leads to loss of dimerization or kinase activity 
or both.184 It has been previously proposed that the N-terminal CBD of eEF-2K could play a similar role, 
with CaM perhaps substituting for the second protomer184 in activating the enzyme.  
 The established view for the activation of CaM-regulated kinases is the so-called “release of 
inhibition” mechanism172 in which the active site is blocked by a “pseudo-substrate” moiety that also 
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contains a CaM recognition element; engaging Ca2+-CaM releases this inhibition and allows kinase 
activation. As mentioned previously, eEF-2K appears to be activated by a different mechanism. It has 
been shown by Tavares et al.37 that the presence of Ca2+-CaM has a drastic effect on the intrinsic 
catalytic activity (>2000-fold increase in kcat) without major changes in the affinity for a peptide substrate 
(~2-fold decrease in the apparent KM) and a decrease in the affinity for ATP (~8-fold increase in the 
apparent KM). Our HXMS results are indeed consistent with these data with no decrease in solvent 
protection seen at the catalytic cleft of TR (or for that matter, for any other region) upon engaging Ca2+-
CaM. The HXMS data that shows increased protection in regions on the KD that are well separated in 
space including on the PBP and indeed on the regions of the CTR that are spatially proximal to the kinase 
active site in our computational model, suggest significant conformational changes in TR upon Ca2+-CaM 
binding. These data are in line with the NMR analysis that reveals spectral perturbations spreading 
across most of the KD in the presence of Ca2+-CaM. We suspect that this set of conformational changes, 
that enhances the intrinsic catalytic activity of eEF-2K, represents the first of the two conformational steps 
in its activation pathway predicted in the kinetics studies of Tavares et al.37. This change likely involves a 
remodeling of the catalytic cleft, enabled by a series of conformational transitions propagating from the N-
lobe of the KD, the site of engagement with CaM, as suggested by our NMR analysis. This remodeling is 
perhaps also facilitated by a rearrangement of the relative positions of the KD and CTR. The role of the 
CTR in modulating the activity of eEF-2K is highlighted by the previous observation that the isolated KD is 
incapable of phosphorylating not only eEF-2, but also a substrate peptide. However, this ability can be 
restored in trans by the CTR.48 Our studies also highlight the fact that Ca2+-CaM binding induces greater 
order at the PBP. This change could be perceived as a conformational rearrangement in preparation to 
accommodate phosphorylated T348 leading to the second conformational transition predicted in the 
kinetics studies resulting in a state with the highest activity towards substrate.37 While our current studies 
provide insight into the overall organization of the structural domains of TR and of CaM in the context of 
the Ca2+-CaM•TR complex and evidence of significant conformational changes (Figure 5.20) induced by 
Ca2+-CaM binding to TR priming it to enable efficient auto-phosphorylation on T348, the precise nature of 
these transitions await high resolution structures of the complex and more detailed analyses of dynamics 
using NMR and/or computational approaches. In this regard, the stripped-down yet functional TR 
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construct provides an added benefit for future structural studies - since it is missing many of the segments 
that are expected to be disordered in full-length eEF-2K, it could, in principle, be an excellent candidate 
for crystallization trials. Our extensive efforts to obtain crystals of full-length eEF-2K have not yielded any 
positive results. Further, the smaller size of TR (60 kDa) should also ease the performance of detailed 
NMR analyses that would have been more problematic in full-length eEF-2K (82 kDa).  
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Figure 5.19. The dimeric structure of the C-terminal α-kinase domain of the Ca2+-dependent 
transient receptor potential (TRP) channel, ChaK (PDB: 1IAJ). The two protomers that form a head-
head domain-swapped dimer through the exchange of an N-terminal helix, are colored red and blue, and 
shown in ribbon and surface representations. 
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We note that the current studies probe events involved with Step 1 of the two-step activation 
process of eEF-2K. Thus, our analyses are sensitive to all conformational changes following the 
engagement of Ca2+-CaM that lead to a state capable of efficiently auto-phosphorylating on T348. An 
additional set of conformational transitions are expected after T348 phosphorylation and engagement of 
the PBP by phospho-T34837 (Step 2). These latter events will be probed by future studies on T348-
phosphorylated TR. 
5.5 Materials and Methods 
5.5.1 Expression and purification of His6-SUMO-tagged TR 
A His6-SUMO tagged TR construct was cloned into a pET15b expression vector (Novagen) between the 
NdeI and BamHI restriction sites and transformed into BL21 DE3 E. coli cells (New England Biolabs) for 
expression. The cells were plated on ampicillin plates and incubated overnight at 37 °C. A single colony 
was inoculated into 10 mL of LB medium (containing 100 mg/L of ampicillin) and grown overnight at 37 
°C. The overnight culture was inoculated into 0.4 L of LB medium and grown at 37 °C until the culture 
reached an A600 of 0.8, at which point the temperature was reduced to 18 °C and expression was induced 
by the addition of IPTG to a final concentration of 0.4 mM. Post induction, the cells were grown for 16 
hours and harvested by centrifugation at 2820 × g for 30 minutes.  The cell pellet was re-suspended in 50 
mL of cold lysis buffer (20 mM Tris, 200mM NaCl, 0.1% β-mercaptoethanol, 0.1% Triton X-100, 10 mM 
imidazole and 1 tablet of Roche Complete Mini EDTA-free inhibitor tablet, at pH 7.5); all subsequent 
steps described below were carried out at 4 °C. The cells were lysed by sonication and cell debris was 
removed by centrifugation at 10800 × g for 30 minutes. The soluble lysate was added to a 5 mL (bed 
volume) Ni-NTA affinity column (Qiagen) previously equilibrated with lysis buffer and incubated for 1 hour 
with end-over-end rotation. The column was then washed extensively with washing buffer (20 mM Tris, 
200 mM NaCl, 0.1% β-mercaptoethanol, 20 mM imidazole, pH 7.5) and the bound protein was 
subsequently eluted with 50 mL of elution buffer (20 mM Tris, 200mM NaCl, 0.1% β-mercaptoethanol, 
250 mM imidazole, pH 7.5). The His6-SUMO tag was cleaved by the addition of ULP1 protease (1ug per 
50 mL of elution) and dephosphorylated with λ-phosphatase (New England Biolabs) during overnight 
dialysis into cleavage buffer (20 mM Tris, 200 mM NaCl, 0.1% β–mercaptoethanol, 1 mM MnCl2, pH 7.5). 
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The effectiveness of cleavage was monitored by 12% SDS-PAGE gels. The cleavage reaction was 
quenched by addition of 0.1 mM AEBSF. The cleaved protein was further purified via ion exchange 
chromatography using a 5 mL Hitrap Q HP column (GE Life Sciences) applying a linear NaCl gradient 
from 0.2 to 0.8 M in a buffer containing 20 mM Tris, 2 mM DTT at pH 7.5. The purified protein was then 
concentrated using spin columns and further purified by gel filtration chromatography using a Superdex 
200 10/300 GL (GE HealthCare Biosciences) column pre-equilibrated with a buffer containing 20 mM 
Tris, 200 mM NaCl, 2 mM DTT, 1 mM CaCl2 at pH 7.5 (referred to as SEC buffer). 
 
 
 
Figure 5.20. Model of CaM Mediated eEF-2K Activation. A model for Step 1 of the two-step activation22 
of eEF-2K by Ca2+-CaM is shown schematically. The CBD (orange) is engaged by Ca2+-CaM (light blue) 
with the loss of 2 Ca2+ ions (from the C-lobe of CaM). This primary interaction is supplemented by 
additional weak interactions of CaM (most likely through the CaM N-lobe) with the N-lobe of KD (blue). 
The docking interaction between CaM and the eEF-2K KD leads to conformational changes that are 
transmitted to remote sites on the latter (represented schematically by the yellow dashed arrows) 
including the phosphate binding pocket (PBP, cyan), the catalytic center (grey oval) and the CTR (purple). 
This results in a conformation (extreme right) that is primed to efficiently phosphorylate on T348 (yellow 
with black outline). Thus, Ca2+-CaM binding to eEF-2K may be conceived as leading to the formation of a 
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transient “excited-state” configuration of the binary complex that subsequently relaxes to a stable pre-
chemistry complex primed to efficiently phosphorylate on T348. 
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Calmodulin was expressed and purified as described previously53. To generate the Ca2+-CaM•TR 
complex, purified CaM in a SEC buffer was added to the TR samples in the same buffer in a 1:2 molar 
ratio followed by gel filtration (as above) to purify the 1:1 complex. Fractions containing the pure Ca2+-
CaM•TR heterodimer were collected and concentrated using spin columns to final concentrations ranging 
from 40 to 50 µM for hydrogen exchange mass spectrometry and chemical crosslinking experiments. 
5.5.2 Analysis of TR activity in vitro 
Measurement eEF-2K activity against a peptide substrate (Pep-S) was carried out as described 
previously, in the following buffer: 25 mM HEPES, pH 7.5; 2 mM DTT; 10 µg/mL BSA; 50 mM KCl; 10 mM 
MgCl2; 100 µM EGTA; 150 µM CaCl2; 2 µM CaM; 150 µM Pep-S; 1.0 mM [γ-32P]-ATP; and 2.5 nM eEF-
2K G6. Calmodulin was omitted from this buffer for assays in the absence of CaM36,54. All experiments 
were performed in duplicate. 
5.5.3 Generation of the TR-pcDNA3-HA-FLAG construct 
Overlap-extension mutagenesis was used to directly generate TR starting with the wild-type eEF-
2K-pcDNA3-HAF construct described previously37. Primers were designed to incorporate ends 
compatible with ligation-independent cloning (LIC). The mutagenesis product and amplified pcDNA3-HAF 
vector were digested with T4 DNA polymerase in the presence of dATP or dTTP, respectively. The 
digested products were annealed at room temperature and transformed into DH5α, purified, and 
sequenced. 
5.5.4 Analysis of TR activity in MCF-10A eEF-2K-/- cells 
MCF-10A cells lacking endogenous eEF-2K (eEF-2K-/-)37 were plated at a density of 150,000 cells 
per well in 6-well tissue culture plates. The following day, cells were transfected using Lipofectamine 
3000, according to the manufacturer’s instruction (using 2 µL P3000 reagent per µg DNA, and 2.5 µg 
DNA per well), with pcDNA3-HAF vectors encoding either wild-type eEF-2K or TR, or an empty control 
vector (CV). Transfection was carried out for 6 hours in DMEM/F12 lacking any supplements, after which 
time the media was changed to complete MCF-10A media. Cells were then allowed to recover for 48 
hours to allow for expression prior to lysis. Lysis and Western blotting for eEF-2K activity were carried out 
as described previously37. The following primary antibodies were used:  eEF-2p-Thr56, #2331, Cell 
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Signaling Technologies (diluted 1:2000); eEF-2, Millipore (diluted 1:20000); eEF-2K (C-12), Santa Cruz 
Biotechnology (diluted 1:500); Actin, Millipore (diluted 1:20000). The following fluorescent secondary 
antibodies (Li-COR) were used at a 1:15000 dilution: Goat anti-Rabbit, 926-32211; Goat anti-Mouse, 926-
68070. Blots were imaged on a Li-COR Odyssey-Sa. 
5.5.5 Inline size exclusion chromatography and native electrospray mass spectrometry 
The TR and Ca2+-CaM•TR complex for native ESI-MS was prepared as described above. The 
samples were injected onto a MAbPac SEC-1 Size Exclusion LC column pre-equilibrated with 50 mM 
ammonium acetate with a continuous flow rate of 50 µL/minute. Elution from the SEC column was 
directly introduced into a Bruker maXis-II ETD ESI-QqTOF mass spectrometer. Spectral averaging of TR 
and Ca2+-CaM•TR complex were performed using the Bruker COMPASS software package. The mMass 
software was then used for baseline correction and smoothing with a 5 Da Gaussian smoothing function. 
The free CaM spectra were similarly processed except the use of a 0.05 Da Gaussian smoothing 
function. 
5.5.6 Hydrogen/deuterium exchange mass spectrometry (HXMS) 
Protein samples (TR in the apo state and the Ca2+-CaM•TR complex) for HXMS experiments 
were purified as described above. To obtain the deuterium uptake on the global level, exchange was 
initiated by the addition of 2 µL of the sample (either free TR or the Ca2+-CaM•TR complex) in buffer A to 
98 µL of exchange buffer (20 mM Tris, 200 mM NaCl, 2 mM DTT pH 7.5 in 99.9% D2O) to a final protein 
concentration of 2 µM. Samples were then incubated at room temperature for the desired exchange time 
(5, 10, 30 and 240 minutes for TR and 5, 10, 30, 60 and 240 minutes for the Ca2+-CaM•TR complex). The 
exchange was quenched by 2 minutes of incubation on ice followed by the addition 100 µL of quench 
buffer (0.1 M guanidinium hydrochloride, 0.4% formic acid) to reduce the pH to 2.4. All subsequent steps 
were performed in an ice bath. The quenched samples were desalted using a 10 µL C8 Opti-lynx II trap 
cartridge (Optimize Technologies) at a flow rate of 0.12 mL/minute using 0.25% formic acid as the mobile 
phase. The protein was then eluted using a gradient from 10% acetonitrile, 0.25 % formic Acid (Buffer A) 
to 95% acetonitrile, 0.25% formic acid (Buffer B) at a flow rate of 0.1 mL/minute. To determine the 
deuterium uptake at each time-point, the average mass of a non-deuterated reference sample was 
 106 
subtracted from the average mass of each deuterated sample.  
To acquire local exchange profiles (D2O incubation for 5, 10, 30 and 60 minutes was used for 
both TR and the Ca2+-CaM•TR complex), the quenched protein sample was immediately injected over an 
Enzymate BEH Pepsin Column (Waters) with the resulting peptides being desalted by a 10 µL C8 Opti-
lynx II trap cartridge (Optimize Technologies). The digestion with subsequent desalting was performed at 
a flow rate of 0.12 mL/minute using 0.25% formic acid as the mobile phase. The mixture of peptides was 
then resolved with a 50 × 1 mm Hypersil Gold C18 column (Thermo Scientific) and eluted directly into the 
maXis-II ETD ESI-QqTOF spectrometer using a flow rate of 0.04 mL/minute. The resulting peptides were 
identified using the Bruker COMPASS software package. The extent of exchange was assessed using 
the commercial software HDExaminer (Sierra Analytics). HDExaminer identified exchanged peptides from 
raw MS data based on peptide retention times from the COMPASS analysis of an unlabeled reference 
sample. HDExaminer then calculated the deuterium uptake of each peptide after specified exchange 
times. The percent deuterium uptake relative to the theoretical maximum for each peptide was then 
averaged across replicate experiments for each time point. The difference between the average percent 
deuterium uptake of apo TR and the Ca2+-CaM•TR heterodimer peptides was then taken to identify 
regions that experience changes in protection upon CaM binding. All experiments were conducted in 
triplicate, though some peptides could not be unambiguously identified in some replicates. All peptides 
used in the analysis were observed in duplicate or triplicate for each time point. 
5.5.7 Chemical crosslinking mass spectrometry (XLMS) 
Proteins for chemical crosslinking were purified through size exclusion chromatography (as 
above) using columns pre-equilibrated with a buffer containing 50 mM MES, 200 mM NaCl, 1 mM CaCl2 
at pH 6.5) immediately prior to carrying out chemical crosslinking experiments. The crosslinking reaction 
was carried out according to manufacturer’s instructions. Briefly, 0.4, 0.8 or 1.6 mg of 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC) and 1.1, 2.2 or 4.4 mg of N-
hydroxysulfosuccinamide (sulfo-NHS), respectively, were dissolved directly into 1 mL of 50 µM Ca2+-
CaM•TR and incubated at room temperature. After 15 minutes, β-mercaptoethanol was added to a final 
concentration of 0.14%. The samples were then incubated at room temperature for 30 minutes, after 
which a 300 µL aliquot was removed and the reaction was quenched on ice with 50 mM glycine. Another 
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300 µL aliquot was similarly collected and quenched at 1 hour of reaction time. The remaining 400 µL was 
incubated for an additional hour and similarly quenched. The samples were then digested for 16 hours 
with 10µg/ml of MS grade trypsin (Fisher) at 37 °C. The protease digestion was quenched with 1 mM 
PMSF protease inhibitor. The resulting mixture of peptides was subjected to HPLC-ESI-MS/MS analysis 
using Acclaim 300 2.1 × 150 mm C18 column (Thermo Scientific) and maXis-II ETD ESI-QqTOF mass 
spectrometer.  A database of expected crosslinked peptides was generated with xComb185 and a 
MASCOT server (Matrix Science) was used to search the XLMS data for the predicted peptides. False 
positive peptides were identified by comparison of the crosslinked data sets to an untreated control 
sample and analysis of CID fragmentation patterns. 
5.5.8 Production of 13C, 1H Ile-δ1–labeled TR 
Plasmids encoding His6-SUMO-TR and corresponding point mutants were transformed into E. 
coli C41 (DE3) cells. Each Ile in TR was mutated one at a time to Leu (except I232 that was mutated to 
Ala and I522 that was mutated to Ser) by site-directed mutagenesis using the Phusion Master Mix with 
HF Buffer and Q5 High-Fidelity 2X Master Mix (New England BioLabs). Fresh C41 (DE3) colonies were 
inoculated into starter LB cultures supplemented with ampicillin (100 mg/L), grown at 37 ºC until the A600 
reached 0.6, centrifuged (4000 × g for 15 minutes at 4 ºC). The cell pellet was re-suspended in a starter 
M9 medium prepared in D2O and grown overnight. The overnight culture was inoculated into a 0.5 L D2O-
based M9 medium supplemented with 1 g/L 15NH4Cl and 2 g/L 2H-glucose and grown at 37 ºC. When the 
A600 reached 0.5, 50 mg/L (methyl-13C, 3,3-d2) α-ketobutyric acid (Cambridge Isotope Laboratories) was 
added to the growth that was incubated for 1 hour, followed by induction with 0.5 mM IPTG at 18 ºC for 
22 hours. Cells were harvested by centrifugation (2820 × g for 30 minutes at 4 ºC) and re-suspended in 
lysis buffer (50 mM Tris at pH 7.8, 500 mM NaCl, 150 mM KCl, 5 mM β-mercaptoethanol, 20 mM 
imidazole, and 1 mM CaCl2). After lysis by sonication, the lysate was centrifuged (15,000 × g for 30 
minutes at 4 ºC). The supernatant was extracted and incubated with Ni-NTA beads (Qiagen) for 1 hour at 
4 ºC. The beads were poured into an Econo-Column (Bio-Rad), washed with 10 column volumes of lysis 
buffer, and eluted with elution buffer (lysis buffer containing 250 mM imidazole). ULP1 protease (1:1000 
ULP1 to fusion mass ratio) and λ-phosphatase (0.25 nanomoles) were added into the eluate, which was 
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then dialyzed against 4 L dialysis buffer (20 mM Tris at pH 7.5, 150 mM NaCl, 5 mM β-mercaptoethanol, 
and 1 mM MnCl2) at 4 ºC for 16 hours, using 12-14 kDa MWCO dialysis bag (Spectra/Por). Dialyzed 
samples were centrifuged (15,000 × g for 30 minutes at 4 ºC), filtered (0.22 µm), and purified over a 5 mL 
HiTrap Q HP (GE Healthcare Biosciences) column using a linear gradient of 0.2 – 0.8 M NaCl (20 mM 
Tris at pH 7.5, 5 mM β-mercaptoethanol). The TR sample was further purified using a gel filtration column 
(Superdex 200 10/300 GL, GE Heathlcare Biosciences) pre-equilibrated with NMR buffer (20 mM BisTris 
at pH 6.8, 150 mM KCl, 10 mM CaCl2, 5 mM β-mercaptoethanol, and 0.1 % NaN3).  
5.5.9 NMR titrations 
All NMR experiments were performed at 25 ºC on a Bruker Avance spectrometer operating at 
800 MHz equipped with a cryogenic probe capable of applying pulsed field gradients along the z-axis.  A 
37 µM sample of 13C,1H-Ile-δ1, U-[15N,2H]-labeled TR in NMR buffer prepared in D2O was used in the 
CaM-titration experiments using 13C, 1H HMQC spectra (64 and 512 complex points in the 13C and 1H 
dimensions, respectively, with corresponding sweep-widths of 7 and 12.5 ppm). In addition to apo TR, 
data were obtained in the presence of 0.25, 0.5, 1, 2, and 4 molar equivalents of U-2H-labeled CaM. All 
spectra were processed using NMRPipe130 and analyzed using NMRViewJ131. Assignment of the Ile-δ1 
resonances were obtained using 13C, 1H SOFAST-HQMC180 spectra of 13C,1H-Ile-δ1-labeled TR mutants 
at 700 MHz (64 or 96 or 128 and 512 complex points in the 13C and 1H dimensions, respectively, with 
corresponding sweep-widths of 7 and 13.3 ppm) in the absence/presence of various molar ratios of 
unlabeled CaM. The concentrations of the various Ile mutants of TR in the NMR samples varied from 11.4 
to 46 µM. 
5.5.10 Generation of a computational model of the KD•CTR complex 
For the first step in the generation of the KD•CTR496-725 complex, the structure of a C-terminal 
fragment encompassing residues L496-E725 was generated utilizing the NMR structure of the HR23 
construct (G562-E725) together with ab initio modelling186 and RosettaDock187 as implemented in the 
Rosetta3.7 suite. Fragment libraries for ab-initio modeling were generated using the Robetta server188. 
Initially, a fragment corresponding to residues V502-S575 (CTR502-575) was modeled ab initio. The 
calculation resulted in partial convergence for the fragment encompassing residues E541-S575 (CTR541-
 109 
575) that was consistently modeled as containing two antiparallel helices. Next, from the lowest energy 
structure belonging to the HR23 NMR ensemble, we extracted the folded portion that corresponds to 
CTR597-725. A loop spanning residues Q624-C631 was also removed, since it could favor a different 
conformation in the presence of the neighboring regions that were missing in the NMR construct. The 
previously described CTR541-575 fragment was then docked onto the CTR597-725 fragment using two 
harmonic restraints and a 15 Å tolerance between the N-terminal residue (G597) of CTR597-725 and the C-
terminal residue of CTR541-575 (S575), and between residues L564 of CTR541-575 and D609 of CTR597-725, in 
order to preserve the expected anti-parallel orientation of the helices. The predicted loop that links these 
two regions (S575-G597), as well as the  Q624-C631 loop were then modeled using the kinematics 
closure (KIC)189 method implemented in Rosetta, resulting in the final model for CTR541-725. It is notable 
that the newly constructed Q624-C631 loop assumed a conformation that was similar to that observed in 
the experimental NMR structure of the HR23 construct.  
Next, we modeled a CTR496-562 fragment; it should be noted that this in-silico construct shares the 
541-562 helical region with the previously described CTR541-725 model. For CTR496-562 however, the native 
eEF-2K sequence 541EKGEEWDQESAVFHLEHAANLG562 (that forms the N-terminal helix of CTR541-725) 
was modified using RosettaRemodel190, such that the hydrophobic residues that contact the neighboring 
helix on the C-terminal side (bold residues) (in the context of the modelled CTR541-725) were converted to 
polar residues to form an artificial capping interface in the context of CTR496-562. This was done in order to 
prevent packing of the native hydrophobic face into the hydrophobic interior of CTR496-562 and thus 
resulting in non-native contacts. This led to the following sequence: 
541EKGEEWDQESQVFHKEHKSNQS562. With these mutations in place,  an ab initio model of CTR496-562 
was then constructed. The resulting CTR496-562 was then superimposed onto the modelled CTR541-725 
using their overlapping regions (residues E541-G562). At this point the redundant E541-G562 fragment 
within the CTR496-562 construct was removed, together with the neighboring  G536-C540 loop. On the  
CTR541-725  model, the disordered E541-D546 fragment was also removed. A continuous CTR496-725 was 
obtained by modelling the missing loops using the KIC methodology. Finally, the resulting structure of 
CTR496-725 was relaxed in the Rosetta force field using default parameters. 
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 Next, the CTR496-725 fragment was docked onto the modeled KD (H103-P330) using RosettaDock. 
The observed inter-domain crosslinks (K516/K517-D248 and K517/K520-D248/D249; IntraTR-2, 3 in 
Table 5.1) were used as ambiguous restraints using a flat harmonic scoring function with zero penalty 
range of 15 Å. A total of 20000 calculations were attempted, of these, 1205 resulted in no violations of 
restraints and successful structure output. Docked decoys with interface energies ranging from -5 to -10 
(Rosetta Energy Units) were used for further analysis (264 total). The interface RMSD values of the 
decoys were calculated within RosettaDock using the local refinement protocol with one round of 
minimization which leads to rescoring of all decoys with the lowest energy decoy as reference. 
5.5.11 Small angle X-ray scattering (SAXS) 
The Ca2+-CaM•TR complex for SAXS experiments was purified as described above. Samples 
were concentrated using Amicon Ultra 10K MWCO spin concentrators (Millipore) to final concentrations of 
1.9 or 6.4 mg/ml (for Ca2+-CaM•TR). Flow through from the concentrator was used as a reference to 
subtract buffer contribution from the scattering data. All experiments were performed on a Rigaku 
BioSAXS 1000 instrument equipped with a Dectris Pilatus 100K detector attached to one port of an FRE+ 
Superbright rotating copper anode X-ray generator.  
Scattering data was analyzed using the ATSAS 2.8.3 software package191. The particle 
distribution function was calculated using GNOM181 and the molecular envelopes were calculated using 
DAMMIF192. In all 20 structures were calculated for each concentration and selected based on normalized 
spatial deviation values (NSD) and an average envelope was determined using DAMAVER193. The 
frequency map and the average model computed by DAMAVER was utilized in a DAMMIN194 run to 
generate the final refined molecular envelope. In addition, SAXS data was also collected for TR alone at 
concentrations of 3 mg/mL, 5 mg/mL and 10 mg/mL. No detailed analysis was performed in these cases 
since an initial inspection suggested concentration dependent aggregation.  
 The 6.4 mg/mL SAXS dataset was used together with the structures of the Ca2+-CaM•CBD 
complex53 (a representative structure was chosen from the NMR ensemble) and the KD•CTR496-725 
complex (from above) were to generate the overall topology of the Ca2+-CaM•TR complex using 
CORAL182. To allow some flexibility between modules,  
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residues W99 and A100 were removed from the C-terminus of CBD in the Ca2+-CaM•CBD complex and 
the new C-terminal residue (P98) was linked to A108 of the KD  
 (after removing the H103-I107 segment at the N-terminus) in the KD•CTR496-725 complex using a 9-
glycine linker. The C-terminal P330 of the KD was then linked to the N-terminal L496 of the CTR both in 
the context of the KD•CTR496-725 complex using a 40-glycine linker (including the 6-glycine linker native to 
TR). Calculations were performed using the entire SAXS dataset or the range listed in Table 5.3 
(q=0.0238-0.2293) using different orientations of Ca2+-CaM•CBD relative to the KD•CTR496-725 complex, 
including one in which the former was placed at a significant distance without linking the C- 
 terminus of the CBD to the N-terminus of the KD in the starting configuration. Overall similar organization 
of domains was obtained in all cases irrespective of starting configuration. The final structure generated 
by CORAL was superimposed on the DAMMIN refined molecular envelope (from above) using 
SUPCOMB195.  
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Chapter 6 – Future Directions 
6.1 Overview of Future Directions 
 The mechanism of CaM-mediated eEF-2K activation was successfully characterized by 
combining biochemical and biophysical methods including NMR, hydrogen/deuterium exchange mass 
spectrometry, chemical crosslinking and SAXS. As described in Chapters 4 and 5, we have generated a 
structural model for the previously uncharacterized C-terminal region of eEF-2K as well as a model of the 
Ca2+-CaM•TR complex. Further, we have identified regions within TR that are altered upon CaM binding. 
While this is a critical first step in eEF-2K activation, phosphorylation of T348 represents the next critical 
step required for eEF-2K to adopt its fully active conformation (generating state S3 from state S2 in 
Figure 1.2). Given that our results suggest that CaM binding has an allosteric effect on the phosphate 
binding pocket into which phospho-T348 docks prior to the phosphorylation event. This raises intriguing 
possibilities of coupling between these two steps of the proposed activation pathway described earlier. 
Additionally, a second site of auto-phosphorylation (also a PKA target), S500 (Figure 1.2), has been 
shown to have a complementary role in eEF-2K activation.196,197 In addition, to the events subsequent to 
T348 phosphorylation, analysis the structural effects when both T348 and S500 are phosphorylated 
would provide insight into the functional roles characterization of the later steps of the eEF-2K activation 
pathway.  
6.2 Characterization of the Mechanism of eEF-2K Activation through T348 Phosphorylation 
 The experimental approach described in Chapter 5 could be applied to characterize the 
conformational following T348 phosphorylation with a few minor modifications. We anticipate that 
interaction of phosphorylated T348 with the phosphate binding pocket within the C-lobe will further 
stabilize an active conformation of the kinase domain. HXMS experiments will yield information about 
structural perturbations and dynamics changes in response to T348 phosphorylation. NMR analysis of Ile-
δ1 chemical shifts could provide an orthogonal approach to further identify residues that are perturbed 
upon T348 phosphorylation. SAXS analysis of these activation states can also be used to further 
characterize major changes in the overall shape of the protein in response to T348 phosphorylation. 
 113 
6.2.1 Isolation of T348 phosphorylated TR 
 Isolation of TR phosphorylated on T348 would greatly facilitate analysis of the second step of the 
proposed eEF-2K activation pathway (Figure 1.2). Multiple approaches could be taken to generate a 
homogeneously T348 phosphorylated species without additional phosphorylation events. To ensure that 
we control the phosphorylation state of TR, we first treat the protein sample with a phosphatase to 
generate a homogeneously dephosphorylated species. Incubation of eEF-2K with Ca2+-CaM and 
Mg2+•ATP in vitro has been show to result in rapid autophosphorylation of eEF-2K on T348 as well as 
phosphorylation of S500 on a much longer timescale.36 Due to significantly slower autophosphorylation 
rates of S500 compared to T348, optimization of the autophosphorylation assay may allow the production 
of homogeneously phosphorylated T348/non-phosphorylated S500. The phosphorylation state of TR can 
be characterized by mass spectrometry of the intact protein (to determine the number of phosphorylated 
residues within TR) and trypsin digested peptides (to determine the location of the phosphorylated 
residues). If heterogeneous phosphorylation states are unavoidable, a S500A mutant form of TR could be 
utilized to ensure that only T348 is the only available autophosphorylation site. This mutant would allow 
complete and homogeneous phosphorylation of T348 through extended in vitro autophosphorylation of 
TR. However, it would then be important to confirm that the S500A mutation does not lead to any 
changes in the overall structure/dynamics of TR. 
6.2.2 HXMS Analysis of Step Two (T348 Phosphorylation) of the eEF-2K Activation Pathway 
 A similar methodological approach as described in Chapter 5 could be utilized to characterize the 
mechanism through which phosphorylation of T348 mediates activation of eEF-2K. Briefly, intact mass 
HXMS of dephosphorylated and T348 phosphorylated Ca2+-CaM•TR would be performed to determine 
the relevant time range to investigate as well as characterize the global effect of T348 phosphorylation on 
the structure of TR and CaM. Local exchange rates will then be determined to identify regions within TR 
and CaM that are altered by T348 phosphorylation. Comparison of the T348 phosphorylated state of TR 
in the presence and absence of CaM would also allow further dissection of the effects of Ca2+-CaM 
mediated activation as opposed to T348 phosphorylation. 
 We anticipate that phosphorylation of T348 will reduce the rate of deuterium uptake by TR 
compared to the fully dephosphorylated CaM bound state. This is due to stabilization of a stable active 
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conformation of TR, which is likely to be more compact and less dynamic than dephosphorylated TR. As 
described above, CaM induces allosteric changes to the phosphate binding pocket that phosphorylated 
T348 docks into (Chapter 5). While it is not expected that phosphorylated T348 directly interacts with 
CaM bound to TR, it is possible that allosteric communication between the phosphate binding pocket and 
the CaM binding interface may alter or stabilize CaM binding thus resulting in changes in the protection of 
CaM bound to TR. 
  While it is impossible to predict all of the local effects of T348 phosphorylation a priori, we 
anticipate that the phosphate binding pocket will become more protected in the T348 phosphorylated 
state. We suspect that coordination of the T348 linked phosphate group by K205, R252, and T25437 of 
eEF-2K would decrease the dynamic behavior of this region, thus reducing the rate of local deuterium 
uptake. Sequestering a peptide onto the C-lobe of the kinase domain would also reduce the average 
solvent exposure of the surface area in this region, which would be expected to further reducing the rate 
of deuterium uptake. Our model of the spatial orientation domains within TR suggests that the pocket is 
adjacent to the N terminal region of the C-terminal domain, which could lead to the possibility that binding 
of phosphorylated T348 to the phosphate binding pocket would also perturb this region of the C-terminal 
domain.  
6.2.3 NMR Analysis of Step Two (Thr348 Phosphorylation) of the eEF-2K Activation Pathway 
Comparison of 13C,1H HMQC spectra of 13C,1H-Ile-δ1-labeled dephosphorylated and T348 
phosphorylated Ca2+-CaMTR offers an orthogonal method to further characterize this system. Three of 
the Ile residues within TR (I518, I237, I251) are located in proximity to the phosphate binding pocket. We 
anticipate that these residues will all be significantly perturbed by T348 phosphorylation.  
6.3 Characterization of the Mechanism of eEF-2K Activation through Additional Phosphorylation 
Events 
 Phosphorylation of S500 or a phosphomimetic mutant S500D have been shown to induce CaM-
dependent but calcium independent activation of eEF-2K (Figure 6.1).149,173,196 To characterize the 
mechanism of this activation pathway a similar approach could be taken as described in Section 6.2 
above. A S500D mutant of the TR construct would facilitate these studies by ensuring a homogeneous 
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sample that could be phosphorylated on T348 as described above. Due to the calcium independent 
activation it would be especially interesting to determine the effect of this construct on the conformation of 
CaM. Therefore, the analysis of free CaM would be a useful reference for comparison to the S500D-TR 
(and/or S500D, pT348-TR) bound states. 
 While all of the additional regulatory phosphorylation sites of full-length eEF-2K (see Figure 1.1) 
are missing in the TR construct (see Figure 5.1A), the structural and dynamics changes upon additional 
regulatory phosphorylation will have to rely on full-length eEF-2K, that has proven to be less biophysically 
tractable than the TR construct. Thus, further optimization of sample/experimental conditions will be 
needed to pursue analogous studies on full-length eEF-2K. 
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Figure 6.1 – Proposed three-step mechanism for eEF-2K activation. Resting eEF-2K (state S1) forms 
a complex with calcium bound calmodulin (state S2*) and undergoes a conformation transition (T1) to a 
state (S2) that is able to phosphorylate on T348. Rapid auto-phosphorylation on T348, leading to an 
excited state S3*, enables phosphorylated T348 to interact with a phosphate binding pocket on the C lobe 
of the kinase domain, leading to a second conformation transition (T2), generating a state of eEF-2K (S3) 
that has the highest activity towards its substrate eEF-2. Subsequent phosphorylation of S500 (state S4* 
and S4) by eEF-2K or PKA induces CaM dependent but calcium independent activation (T3) through a 
yet unknown mechanism. 
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